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Introduction
1. The Cost of Breast Cancer.
World-wide, breast cancer is the most common malignant tumour
affecting women. It accounted for over half a million histologically
confirmed cases in 1980 which is more than 18% of all cases of
malignancy (Tomatis, 1990). The contribution of this disease to the
total burden of malignancy is particularly marked in the Western
world in which it forms the single largest diagnostic entry in cancer
registers. In developing nations as a whole, breast cancer ranks second
behind cervical cancer in actual numbers of diagnoses (Parkin et al.,
1988).
In Scotland there were more than 2500 new cases of breast cancer in
1987; the last year for which complete records are available. 12% of
this total involved women under age 45 and 0.5% women under 30
(Cancer Registration Statistics Scotland, 1990). It accounted for more
than 28% of all female cancer diagnoses, a significantly higher
percentage than in England and Wales. Age-standardised incidence
rates are also more than 10% higher in Scotland than in the rest of
Great Britain (Whelen et al., 1990).
In terms of mortality, breast cancer is thankfully a more survivable
disease than many other types of malignancy. Even so, in 1990 it
caused 1250 female deaths in Scotland, of which nearly 7% were
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under age 45 and 0.4% under age 30. Almost 4% of all deaths were
due to this disease (Registrar General for Scotland Annual Report,
1990).
Over the last half century mortality rates from malignancy as a whole
have risen nearly two fold. Breast cancer has more than matched this
increase (Registrar General for Scotland Annual Report, 1990). The
rate of increase has not slackened in the decade up to 1987 in which
age-specific rates of breast cancer diagnoses rose by more than 10% in
Scotland (Cancer Registration Statistics Scotland, 1990). The present
life-time risk of breast cancer can be estimated at between one in
twelve or thirteen for the female population. By almost every measure
this disease accounts for a major proportion of morbidity and
mortality in Scotland.
2. Risk Factors in Breast Cancer.
Women who are exposed to factors which predispose to breast cancer
will be at higher risk of the disease than those who are not. Thus
although one in twelve or thirteen women develop breast cancer in the
population at large, many factors will increase or decrease the crude
risk in population sub-groups. Some of these protective and
predisposing factors are described below.
Most obviously, breast cancer incidence increases with age and this is
most marked in peri-menopausal years. Geographical location is also
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important as shown by European migrants who gradually adopt rates
of breast cancer equivalent to the American population after
emigration to the United States (Staszewski and Haenszel, 1965). By
contrast, Japanese migrants are noted to maintain their traditional
culture for longer and their descendants develop a westernised rate of
breast cancer incidence only after one or two generations have passed
(Buell, 1973). The importance of diet is controversial. Although some
studies show that high saturated fat, protein and calorific intake
correlate positively with breast malignancy (Lubin et al., 1986;
Toniolo et al., 1989) and large body mass also increases risk (De
Waard and Baanders-van Halewijn, 1974), other reports reveal no
association between diet and breast cancer incidence (Kolonel et al.,
1983; Willett et al., 1987). Research on Seventh Day Adventists who
have a much lower saturated fat, protein and calorific intake than the
general population suggest that their rates of breast cancer are roughly
equivalent to population figures (Phillips et al., 1980). Hormonal
influences affect overall risk of breast cancer so that late menarche and
early menopause are protective factors against breast cancer
(Trichopoulos and MacMahon, 1972; Staszewski, 1971; Henderson et
al., 1988). An artificial early menopause by means of oophorectomy is
similarly protective (Feinleib, 1968). The effect of pregnancy appears
to be complex. Any pregnancy at advanced age increases risk of breast
cancer, particularly a birth after age 35 (Brinton et al., 1983; Tomatis,
1990). High parity in general protects against breast malignancy
(Tulinius et al., 1978; Brinton et al., 1983). Lactation after childbirth
may have a protective effect during pre-menopausal years and this is
evident even after controlling for age at first birth (Byres et al., 1985;
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McTiernan and Thomas, 1986). The influence of exogenous
oestrogens on breast cancer risk is still unclear but certainly appears to
be small (Brinton et al., 1979; Vessey et al., 1979, 1982; Pike et al.,
1981). Oestrogen replacement therapy seems to have little adverse
effect if used for a short period but may increase risk of breast cancer
if prescribed for more than five years (Henderson et al., 1988).
Biopsy-confirmed benign breast disease may have a positive
association with breast cancer (Hutchinson et al., 1980) although this
has been disputed (Brinton et al., 1979; Chetty et al., 1980). A
previous diagnosis of breast cancer or previous mastectomy however
significantly increases the likelihood of a second breast tumour (De
Waard and Baanders-van Halewijn, 1974; Storm and Jensen, 1986).
Although it is controversial as to whether therapeutic irradiation of a
first breast cancer may slightly increase the risk of a second (Storm
and Jensen, 1986), significant exposure to ionising radiation has been
reported to increase risk of this malignancy in a dose-dependant
manner (Land et al., 1980). Without doubt, one of the strongest
predictive factors for breast cancer is a positive family history, a
recognised association for over a century (Butlin, 1887: Little, 1923;
Lane-Clayton, 1926; Anderson, 1974).
Many of the above studies assign a level of risk to sub-groups which
have been subjected either to predisposing or to protective factors.
Comparison of risk in these sub-groups can be described through the
use of risk ratios, known as relative risk. Thus a four-fold reduction in
risk is found in women who have bilateral oophorectomy before age
40 compared with the general population (relative risk equals 0.25)
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(Feinleib, 1968). Menopause prior to age 45 or menarche at age 16
confers half the risk of breast cancer compared to menopause after age
45 or menarche at age 11 (Trichopoulos and MacMahon, 1972;
Henderson et al., 1988). Childless women have three times the risk of
breast cancer compared with those who have five or more offspring
(Tulinius et al., 1978). The same three-fold elevation in risk is found
in those who have already had breast cancer diagnosed on a previous
occasion (Storm and Jensen, 1986). A five-fold increase in risk is
attributed to women who have their first child after 30 years of age
compared with those giving birth before age 18 (Brinton et al., 1983).
As an example of a very small sub-group subjected to relative risk
analysis; young women for whom both mother and sister have had
confirmed breast cancer have a fifty-fold increase in population risk of
breast malignancy between ages of 20 and 29 (Anderson, 1974).
Relative risks can tell us something about the contribution which
independent factors make towards the total burden of breast cancer.
They are useful in prevention of disease through identification of
factors which might profitably be avoided with consequent reduction
in morbidity from breast cancer. They also indicate the degree to
which high-risk individuals might benefit from intensive breast
screening. An accurate assessment of the value of preventative
measures depends on the evaluation of factors which allow early
detection of malignancy as well as risk factors for the disease itself.
Population mammographic screening to detect early breast cancer has
been shown to reduce mortality from breast cancer to the extent that
for women over fifty years of age the absolute risk of death from this
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disease is 20 - 40% less than in the non-screened group. The cost of
biennial mammography within this population has been favourably
compared to that of cervical screening and transplant services in terms
of number of life-years saved (Miller et al., 1990).
Absolute risks probably provide more directly useful information for
patients than relative risks. Thus although the relative risk of breast
cancer is 12:1 between ages 20 - 39 in women with a first degree
relative previously diagnosed with breast malignancy compared with
those who have no such familial history, the absolute risk in that age-
interval is only 10% (an average of 0.5% per annum). This group
however has a relative risk of 6 : 1 between ages 40 - 59. Although the
relative risk compared with the general population during this later
age-interval is lower than during the earlier age-interval, the absoluteo o o
risk of breast cancer is greater at 14% (an average of 0.7% per annum)
(Anderson, 1974).
The development of our understanding of the importance of family
history in breast cancer begins with Roman historians (Sneider et al
1986). Its subsequent progress is the subject of the next section.
3. Confirmation of a Familial Predisposition : Historical
Perspective.
The earliest known report of a familial aggregate of breast cancer
appeared in a 1837 Massachusetts surgical publication. It was reported
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that the affected person had "scirro-cancer" and that "frequently some
of the relatives of the affected person are cancerous" (Warren, 1837).
Then in 1866 the eminent physician Paul Broca published the detailed
pedigree of "Madame Z". In this family multiple cases of breast and
"liver" cancer extended through four generations and occurred at a
younger age than expected (Broca, 1866). In London, James Paget was
certain from his observations that a tendency to cancer was heritable.
He realised however that such a common disease could occur as a
familial cluster solely by chance (Paget, 1857). Yet in 1887, Butlin
noted that affected relatives of breast cancer patients were almost
invariably in one line of descent (Butlin, 1887). This confirmed that a
heritable factor was the most reasonable cause for familial
predisposition.
The very earliest large analysis of malignancy in relatives of cancer
patients reported that observed risk was less than that expected in the
general population. There were few controls however and pedigree
documentation was poor by modern standards (Pearson, 1904). By
contrast, two later studies in the 1920's included detailed pedigree
ascertainment and revealed an increased incidence of malignancy in
siblings and progeny of individuals with cancer compared with
controls. Furthermore, sisters of patients for whom breast cancer was
the specified malignancy had twice the population risk of breast cancer
themselves (Little, 1923; Lane-Clayton, 1926). Several other reports at
this time suggested a genetic susceptibility to malignancy in animals
and man (Hauser and Weller, 1913; Slye, 1922; Cockayne, 1927). The
possibility that early age of onset of breast cancer might be an
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important pointer to genetic predisposition was reported as early as
1941 (Crabtree, 1941) and appeared to be confirmed in later studies
(Jacobsen, 1946; Anderson, 1972; Lynch et ah, 1976, 1979).
Epidemiological research revealed that first degree relatives of breast
cancer patients were at particularly high risk if the proband had
disease at a young age (Anderson 1974, 1977; Lynch et al.,
1976,1979).
Analyses which assess the risk of breast cancer in women with a
strong family history can be further refined through epidemiological
studies which are subjected to segregation analysis. This type of
analysis not only suggests the probable mode of inheritance but can
also be modified to predict the likelihood that an individual will
develop breast cancer on the basis of her known family history. The
principles involved in this approach are explained in the next section.
4. Confirmation of a Heritable Predisposition : - Segregation
Analysis
In the rare heritable malignant syndromes such as retinoblastoma and
familial adenomatous polyposis (FAP), inspection of a few affected
families generally reveals the mode of genetic inheritance. However
the genetic component involved in common malignancies such as
breast cancer is less clear and its elucidation is complicated by two
factors. First, a common malignancy may occur by chance within a
pedigree. This confuses the apparent pattern of inheritance when it
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occurs within a non gene-carrying branch of the family. Second, a
gene-carrier may not develop the disease because of a relatively low
age-specific penetrance of the disease-associated gene. Thus, for
example, a gene-carrying mother may have offspring with heritable
breast cancer but not develop the disease herself. The distribution of
breast cancer in pedigrees therefore rarely conforms to simple
Mendelian principles. A more complex statistical analysis is required
to determine mode of transmission and is known as segregation
analysis.
This kind of study involves the collection of a large series of breast
cancer probands and in addition confirms disease incidence in close
relatives. The relative likelihood of obtaining the observed distribution
of affected and unaffected pedigree members is computed under
different genetic models such as single gene autosomal dominant,
recessive or polygenic inheritance. A maximal likelihood score is
obtained for each hypothetical model. The score for one model may be
sufficient statistically to exclude other possibilities.
The development of a unified mixed model (Morton and MacLean,
1974) has been applied to data in this kind of analysis. The model
depends on accurate estimation of curves which define age-specific
liability for developing disease (Falconer, 1965, 1967) to which a
major predisposition locus or loci of varying hypothetical transmission
type and penetrance contribute (Elston and Stewart, 1971) together
with a multifactorial component and random environmental factors in
an independent manner. Modifications allow for additional relatives to
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be added to the pedigrees under analysis (Elston and Sobel, 1979;
Lalouel and Morton, 1981).
Many segregation analysis studies have been performed on relatives of
breast cancer probands in recent years. These predominantly confirm
that a single gene transmitted in an autosomal dominant fashion is the
model which best fits the observed data (Williams and Anderson,
1984; Andrieu et al., 1988; Newman et al., 1988; Bishop et al., 1988;
Claus et al., 1991; Iselius et al., 1991). Estimates of lifetime
penetrance of the disease gene are remarkably consistent at 80 - 90%
although predicted population gene frequency varies more widely.
Studies in which pedigrees were ascertained through high-risk
probands give frequencies which vary most and are considered less
reliable than those based on population samples. The latters' estimates
of gene frequency range from 0.0006 to 0.003 (Iselius et al., 1991).
This suggests that between 1 and 6 out of every 1000 women will be at
very high risk of developing breast cancer as a result of an inherited
predisposition. Depending on the actual population gene frequency,
this would account for between 1 and 6% of all female breast cancer.
The different age-incidence curves for gene-carriers and non-gene
carriers however means that this proportion rises to between 4 and
20% of women diagnosed under the age of 45 (Porter et al., 1993).
Following segregation analysis, further refinement of risk assessment
for individuals depends on whether a gene predisposing to breast
cancer is in fact responsible for disease within a particular family and
whether the individual in question carries the gene. There are obvious
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benefits in defining a very small high-risk group of gene-carriers
through genetic screening, rather than a larger medium-risk population
as presently defined through segregation analysis studies.
Pharmacological or surgical prophylaxis and diagnostic organ
screening will become more cost effective in this well defined sub¬
group. Accurate definition of the high-risk group however requires
prior localisation of the susceptibility gene. The means by which this
may be done through the process of linkage analysis is the subject of
the next section.
5. Confirmation of a Heritable Predisposition in Families
and Individuals Linkage Analysis
The approach most commonly used to locate a susceptibility gene for
familial disease is known as linkage analysis (Yates and Connor,
1986). This relies on the known existence of a large number of
polymorphic genetic markers scattered throughout the genome. These
are called markers because they "mark" or "tag" a particular
chromosomal location and can be identified in an individual through
the use of molecular genetic techniques. The term "polymorphic"
simply indicates that more than one allelic form of the marker is found
in the population. Since somatic cells are diploid, individuals will have
one allelic form on each of the two chromosomes on which that
particular marker is located. The individual may be homozygous for
the marker in which case the two alleles will be identical, or
heterozygous in which case two different allelic forms of the marker
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will exist. These markers are heritable. Thus each parent randomly
contributes one or other allelic form to each of the two haploid
gametes which, after zygotic fusion, proceed to constitute the alleles
found in the offspring's genetic make-up.
Markers, like genes, are aligned in linear fashion along each of the
forty-six chromosomes of the cell. In the absence of crossing over and
recombination in meiosis (a purely hypothetical situation), a cancer
susceptibility gene situated on the same chromosome as a marker of
known allelic form will be found to associate with the same marker
allele in all descendants who have inherited the susceptibility gene.
Since crossing-over and recombination however does occur in
meiosis, there is a chance that a susceptibility gene will fail to
associate (segregate) with the same marker allele in the offspring as
the parent. This chance is determined by the genetic distance between
marker and susceptibility locus which in turn is a function of the
physical distance (in DNA bases). Rates of meiotic crossing-over vary
in different chromosomal regions and also differ between oogenesis
and spermatogenesis. Therefore genetic and physical map distances
are not exactly equivalent. Random association of susceptibility gene
and marker alleles within cancer pedigrees suggest either that the
marker under observation is located on a different chromosome to the
susceptibility locus, or if on the same chromosome, distant enough for
frequent recombination events to occur between the two. Such a
phenomenon, where gene and marker are physically distant, ensures
that recombinant gametes make up 50% of the total gamete pool. This
proportion is known as the recombination fraction and is related to
genetic distance in centimorgans in non-linear fashion.. Where marker
and susceptibility gene are in closer proximity a recombination
fraction less than 0.5 will result. The physical distance between the
two loci will also be related to the recombination fraction in a non
linear fashion but when the fraction is small, each cM unit may
represent of the order of one million base-pairs of DNA. Proximity of
these loci results in the observed "linkage" of gene and marker allele
within a cancer pedigree.
Using statistical methodology it is possible to analyse the marker
allele data derived from members of a cancer pedigree. The likelihood
that a given set of allele data might arise without the two loci being in
proximity (recombination fraction equals 0.5) may be calculated. In
addition the likelihood that the data might arise as a result of
proximity of these loci (recombination fraction less than 0.5) may also
be calculated. The ratio of the second to the first calculation (known as
the "odds ratio") gives a value greater than one if it is more likely that
the two loci are in close proximity and less than one if it is less likely.
The logarithm of their value is therefore positive or negative
depending on whether proximity is more or less likely. This
logarithmic value is known as the "LOD" (logarithm of odds) score
and is calculated at various hypothetical recombination fractions
(Morton, 1955). Calculation of LOD scores without recourse to
electronic computational aids is only possible for the simplest of
pedigrees. A LOD score of greater than +3 (odds ratio greater than
1000:1) is generally required to assert linkage. This apparently strict
criterion is due to the difference between prior odds for linkage
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(before allele data is included) and posterior probability of linkage
(which includes allele data). The prior odds for linkage of a
susceptibility gene and any marker locus chosen at random throughout
the genome are 2%. This is because linkage can only be asserted with
statistical force if the locus and gene are in close proximity
(recombination fraction less than 0.3), the odds of which in randomly
chosen markers is 2%. By simplification of Bayes theorem (Emery,
1986), the approximate posterior odds for linkage are the prior odds
(0.02) multiplied by the allele data odds (1000 : 1), which equates to
20 : 1 or 95%. This gives a false positive rate of only 5%, a generally
accepted measure of statistical merit (Risch, 1992).
Modifications of two-point LOD score analysis (likelihood of linkage
between a single marker and susceptibility gene) have been made to
include data from two or more markers in proximity to the gene which
is known as multi-point analysis (Lathrop et al., 1984), and to test the
likelihood that a proportion of families are not linked to the
susceptibility gene which is known as heterogeneity analysis (Ott,
1985). The test for genetic heterogeneity is particularly important
when families with very few affected relatives are analysed (Easton
and Peto, 1990) or when the proportion of unlinked families is high
(Durner and Greenberg, 1992). An acceptable model for use in linkage
analysis studies of common malignancies depends upon accurate
definition of the Mendelian trait as determined through segregation
analysis. The correct mode of inheritance maximises the LOD score.
Sporadic cases in the pedigree however will always reduce LOD
scores, even if a correct mode of inheritance is assumed (Durner and
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Greenberg, 1992). It is unfortunate that heritable breast cancer
pedigrees are predicted to have a high level of sporadic disease
contamination and furthermore exhibit genetic heterogeneity. These
limitations in linkage analysis as applied to breast cancer have resulted
in the necessity for considerable effort to collect large breast cancer
pedigrees in which ascertainment of malignant disease is complete.
The number of pedigrees for which data must be accumulated to reveal
reliable linkage to a breast cancer locus will undoubtedly be greater
than that required for the rarer strictly Mendelian malignant
syndromes which are genetically homogenous, in which disease is
seldom sporadic and penetrance is almost complete at a relatively
young age. This is reflected in the recent successful linkage of loci for
retinoblastoma, FAP, multiple endocrine neoplasia type 1 and II, and
neurofibromatosis types I and II (King, 1990). In contrast, the family
database necessary for veritable linkage studies in familial breast
cancer is too large for small centres to accumulate adequate data
independently. It is possible however that national and international
collaboration may be able to circumvent those economy-of-scale
limitations through pooling of family genetic information and
centralised statistical analysis.
6. Elucidation of the Genetics of Heritable Malignancy.
Investigations into the genetics of well defined malignant syndromes
which are inherited in an obvious Mendelian fashion might tell us a
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great deal about the nature of the heritable component of more
common and genetically complex malignancies such as breast cancer.
a) Retinoblastoma
In 1971, Knudson reported certain observations on the numerical
distribution of distinct retinoblastoma primary tumours in individuals
diagnosed with this malignancy (Knudson, 1971). He noted that in
cases with bilateral disease the proportion of affected offspring closely
approximated the 50% expected from a dominant mode of inheritance.
Furthermore he recognised that a significant fraction of cases in which
only unilateral retinoblastoma developed also had offspring with the
disease. From the actual numerical distribution of either unilateral or
bilateral tumours among those who either did or did not provide
evidence for heritability of disease, statistical methods were employed
which determined that a heritable case would on average develop three
tumours. Poisson statistics explained why very occasionally a gene-
carrier might fail to develop even a single tumour.
Knudson found that the proportion of sporadic to heritable cases was
best explained in terms of a "two-hit" theory of carcinogenesis. By this
model, a single gene would be responsible for protection against both
heritable and sporadic retinoblastoma. If a single copy of this gene
within the susceptible cell should be "hit", then that in itself would be
insufficient for malignant transformation as the normal copy would
continue to allow the cell to function in a non malignant way.
However if the second copy should also be "hit" then the cell would
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take on the malignant phenotype. According to this hypothesis the first
mutation could be either somatic or germline while the second would
always be somatic. Knudson calculated that the chance of any one cell
susceptible to retinoblastoma receiving a somatic "hit" was very low at
approximately 2 x 10~7 per annum. The chance of that same cell
receiving a second mutational "hit" would be the square of this value.
If however the first "hit" were to be inherited and therefore present in
every susceptible cell, then the overall chance of a malignant
phenotype developing would be much greater. This explained why the
heritable form of retinoblastoma resulted in a mean of three tumours
per gene-carrier which compares with a figure of only seven per
million non gene-carriers who develop even a single tumour. The
observed incidence of heritable and sporadic forms of retinoblastoma
was thereby related to germinal and somatic mutations rates (Knudson.
1975). A similar two-stage model was also proposed as likely to
account for the observed age-incidence curves in sporadic and
heritable breast cancer with hormonal influences affecting the kinetics
of growth of normal breast tissue and consequently the likelihood of
somatic mutation (Moolgavkar et al., 1980).
The case for a two-stage carcinogenic model in retinoblastoma has
been strengthened by experimental evidence. In 1963 a microscopic
deletion involving one third of the long arm of a chromosome in the
13 - 15 group was detected in normal fibroblasts and blood
lymphocytes of an infant who had developed the familial form of
retinoblastoma (Lele et al., 1963). The homologous chromosome
appeared normal on cytogenetic metaphase analysis. Later work
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revealed that the deletion was more precisely located to chromosome
band 13q 14 (Grace et al., 1971; Knudson et al., 1976; Salamanca-
Gomez et al., 1984). Further cytogenetic studies showed that deletion
of this part of chromosome 13 or absence of the whole chromosome
was a common feature of tumour cells from sporadic retinoblastoma
(Balaban et al., 1982; Gardner et al., 1982; Benedict et al., 1983a).
This suggested that the same genetic locus might be involved in both
forms of the disease. The gene encoding the human enzyme esterase D
had previously been assigned to the same chromosomal location,
namely 13q 14 (van Heyningen et al., 1975; Sparkes et al., 1980). The
enzyme activity of esterase D was found to be reduced by about 50%
in individuals with both heritable retinoblastoma and a microscopic
13q deletion (Sparkes et al., 1980). It was revealed that esterase D also
exhibited polymorphic characteristics with two different human
isoenzymic forms (Hopkinson et al., 1973). In pedigrees with the
familial form of retinoblastoma a single isoenzymic pattern was
observed to segregate with individuals who were affected by the
condition (Sparkes et al., 1983; Connolly et al., 1983). Linkage 1
analysis revealed tight linkage of the esterase D gene to the locus
responsible for retinoblastoma giving a maximal LOD score of greater
than +3 at zero recombination.
The fact that 50% esterase D activity was associated with a
cytogenetic deletion of one of the pair of chromosomes 13 within the
germline in heritable retinoblastoma pedigrees was suggestive of the
first "hit" in Knudson's hypothesis; a damaging genetic event at the
germ-cell level which removed one of the copies of both the
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retinoblastoma and esterase D genes. Since not immediately lethal,
such a deletion became heritable. Evidence that a further event might
be necessary for malignant transformation of any one somatic cell
affected by a single chromosome 13 deletion was soon forthcoming.
An individual with heritable retinoblastoma, 50% esterase D activity
and a presumed sub-microscopic chromosome 13q 14 deletion in all
somatic cells exhibited complete absence of esterase D activity and an
additional missing chromosome 13 in the retinoblastoma tumour cells
themselves (Benedict et al., 1983b). In the same year, another study
suggested that homozygosity of the mutated retinoblastoma tumour
suppressor gene could be achieved through non-disjunction in mitosis
(Cavenee et al., 1983). These data pointed to the second event in the
somatic cells from which tumour originated and in which inactivation
of the sole remaining normal copy of retinoblastoma and esterase D
genes took place. In 1986 a gene was identified at chromosome 13ql4,
all or part of which was frequently deleted in retinoblastoma tumour
cells. The RNA transcript of the gene was also found to be absent in
this tumour type (Friend et al., 1986). This further confirmed
Knudson's hypothesis that the retinoblastoma gene, when mutated, is
recessive at the cellular level in that both copies of the gene require
inactivation for tumorigenesis. At the level of the whole organism
however the predisposition to retinoblastoma is transmitted from
generation to generation in an autosomal dominant fashion.
The observations that familial retinoblastoma arises from an
inactivated "tumour suppressor gene" contrasts with the concept of
action of dominant oncogenes (Huebner and Todaro, 1969) in which
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normal "proto-oncogenes" become activated and their overactivity
stimulates the tumorigenic process. Activation of oncogenes can occur
through a number of pathways such as retroviral infection,
chromosomal translocation, limited mutation and genetic amplification
(Spandidos and Anderson, 1989).
Very recently, inheritance of a mutated copy of the RET proto-
oncogene, localised to chromosome 10qll.2, has been implicated in
the autosomal dominant malignant traits of Multiple Endocrine
Neoplasia (MEN) types 2A and 2B, and also Multiple Thyroid
Carcinoma (Mulligan et al., 1993, 1994). The RET proto-oncogene
encodes a tyrosine kinase receptor; these are cell surface molecules
which transduce signals for cellular differentiation. The RET proto-
oncogene is activated, structurally rearranged and over-expressed in
tumour cells from medullary thyroid carcinoma and
phaeochromocytoma. Germline mutations in the RET gene which
predispose to MEN2A typically involve bases which code for
conserved cysteine residues. Since only one mutant allele is sufficient
for both inheritance of the trait in the germline, and additionally
tumour development in susceptible individuals, it appears likely that a
dominant oncogene rather than a classic tumour suppressor gene
mechanism is acting in this syndrome (Mulligan et al., 1993).
Interestingly, inactivation of the RET proto-oncogene through
mutation appears to cause the non-malignant heritable trait of
Hirschsprung's Syndrome which is characterised by an aganglionic
lower colonic segment, indicating the wide-ranging role which the
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RET gene plays in control of growth and development (Edery et al.,
1994).
Although it is recognised that oncogenes do not have an important role
in tumorigenesis through control of cell proliferation, in most familial
malignant traits oncogenic activity is considered to be particularly
crucial subsequent to the initial transformation stage (Steel, 1989). The
importance of an "anti-oncogene" or "tumour suppressor gene" in the
development of familial retinoblastoma has led to the search for
similar genes in other heritable malignant conditions transmitted in
autosomal dominant fashion, such as F.A.P.
b) Familial Adenomatous Polyposis (FAP)
The report of a cytogenetic germline deletion in chromosome 5q in a
mentally retarded individual who exhibited features of Gardner
syndrome (FAP plus extra-colonic manifestations) hinted at the
possible location of a tumour suppressor gene in this condition
(Herrera et al., 1986). Linkage analysis studies confirmed the position
of the susceptibility gene for FAP on chromosome 5q21 (Bodmer et
al., 1987; Leppert et al., 1987; Nakamura et al., 1988a; Dunlop et al.,
1989). The gene was identified in 1991 (Kinzler et al., 1991; Nishisho
et al., 1991;Groden et al., 1991; Joslyn et al., 1991).
The distinction at the cellular level between dominant oncogenes and
recessive tumour suppressor genes is on occasions difficult to
maintain. For example, analyses of the adenomas which precede
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colorectal carcinoma in FAP seldom yield evidence that a second
allele is lost at the 5q locus, suggesting that the tumour suppressor
gene is co-dominant in the premalignant lesion (Lancet Editorial,
1989).The requirement for a second event to inactivate the FAP
tumour suppressor gene, as predicted in Knudson's hypothesis and
confirmed in retinoblastoma, has however been confirmed in
carcinomas arising in FAP.
The search for mutated tumour suppressor genes in familial
malignancy has thus far yielded an increasing number of susceptibility
genes. This contrasts with a relative paucity of evidence for oncogene
involvement discovered to date. The best chance of elucidating the
genetic component in heritable breast cancer therefore appears to be
through the identification of a susceptibility locus with tumour
suppressor gene characteristics (Steel et al., 1991).
c) Syndromes of Breast Cancer.
Epidemiological studies suggest that there may be distinct heritable
breast cancer syndromes which can be differentiated by the particular
types of non breast malignancy which cluster within them. These may
be classified into seven groups (Lynch and Kullander, 1987a);
(i) Site-specific heritable breast cancer
(ii) Breast-ovarian cancer
(iii) Breast cancer associated with gastro-intestinal malignancy






It appears that the majority of familial aggregates of breast cancer are
best classified within groups (i), (ii) and (iii). The identification of a
purely site-specific pedigree is particularly difficult because a large
family will inevitably have some sporadic malignancies which will
affect classification (Lynch and Kullander, 1987a). It is certainly
apparent that extension of pedigree data from small site-specific breast
cancer families frequently result in the identification of cases of
ovarian and gastro-intestinal malignancy elsewhere in the pedigree
(Steel et al., 1991). Diagnosis of Lynch type II (hereditary non
polyposis colorectal cancer) syndrome requires at least one colon
cancer diagnosis under age 50 (Hakala et al., 1991; Lynch et al.,
1991). There are many examples of breast cancer pedigrees which
fulfil some but not all of the strict criteria for this syndrome (Lynch et
al., 1991). Furthermore ovarian cancer is an important feature of
Lynch type II families (Lynch and Kullander, 1987b).
Until recently it was therefore considered possible that groups (i), (ii)
and (iii) were different phenotypic expressions of the same genotypic
germline lesion. New data, however, has linked hereditary non-
polyposis colorectal cancer (HNPCC) to mutations in mismatch repair
genes on chromosomes 2p22-21 (Fishel et al., 1993) and 3p21 -23
(Bronner et al., 1994). Mismatch repair genes code for enzymes which
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repair mismatched nucleotides. These arise either through physical
damage of genomic DNA, or through misincorporation during DNA
replication, or through genetic recombination of different parental
DNA sequences. Mismatch repair genes play an indispensable role in
DNA replication fidelity, including stabilisation of dinucleotide repeat
elements. Dinucleotide repeats are notably unstable in HNPCC.
Defects in any of these genes results in a general elevation of
spontaneous mutation rates.
The major features of Li-Fraumeni syndrome (Birch, 1990, 1991)
include early age of diagnosis of malignancy with excess soft tissue
sarcoma, bony sarcoma, adrenocortical carcinoma, acute leukaemia,
central nervous system malignancy and breast cancer (Birch et al.,
1990). Widely accepted criteria for this syndrome are based on the
definition of a proband with sarcoma under age 45, a first degree
relative with cancer in this age interval and another first or second
degree relative with either cancer before age 45 or sarcoma at any age
(Li et al., 1988). Recently the germline mutation responsible for
perhaps more than 50% of this family syndrome has been pin-pointed
to the p53 gene on the short arm of chromosome 17 (Malkin et al.,
1990; Srivastava et al., 1990; Metzger et al., 1991; Santibanez-Koref
et al., 1991a, 1991b; Iavarone et al., 1992; De Fromental and Soussi,
1992).
The p53 gene encodes a 53 kiloDalton, 393 amino acid nuclear
phosphoprotein. Since aberrent expression of the gene induced
malignant transformation, p53 was initially classified as an oncogene.
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Subsequent analysis, however, determined that only mutant p53 was
able to transform cells, whereas wild-type p53 failed to do so.
p53 is mutated in a large number of human malignant types (Levine et
al., 1991) and much evidence now reveals p53 to be a tumour
suppressor gene (Lane and Benchimol, 1990; Milner and Medcalf,
1991; Sidransky et al., 1992a). For example, transgenic p53-null mice
develop normally yet exhibit a high tumour incidence (Donehower et
al., 1992). Normal p53 is induced to accumulate in cells with
radiation-damaged DNA. So crucial is wild-type p53 to genomic
stability, that this accumulation occurs via a post-transcriptional
mechanism, so that mutated p53 cannot be produced through
transcription of new RNA from a potentially damaged template
(Kastan et al., 1991). p53 thereby mediates a transient inhibition of
replicative DNA synthesis via arrest of the cell cycle at Gl. Thus
malignant clone formation is inhibited, either to allow repair of
damaged DNA prior to division, or to mediate controlled cell death
(apoptosis).
Wild-type p53 binds DNA in a sequence-specific fashion. Unlike
wild-type p53, mutant p53 protein alone, or normal p53 protein
complexed with viral or hman oncogenes is able to bind to DNA. The
p53 protein core (amino acids 97 - 292) is in large part evolutionarily
conserved and determines p53 conformation, specific binding to DNA
sequences and also sequence-specific transcriptional activity
(Greenblatt et al., 1994). Structurally, this region consists of two large
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loops held by a zinc atom, and additionally a loop-sheet-helix motif
which interacts in the major groove of DNA (Cho et al., 1994).
The majority of point mutations found in human tumour types occur in
five domains which are highly conserved throughout species. This
emphasises the critical nature of these conserved sequences in normal
p53 function. Four of the five highly conserved regions (HCR's) are
located in the central core of the gene (HCR I encompasses amino acid
residues 13 - 19, HCR II; residues 117 - 142, HCR III; residues 171 -
3 81, HCR IV; residues 234 - 258, and HCR V; residues 270 - 286).
Exons 5,7 and 8 encompass most of this central core's highly
conserved regions in which p53 gene mutations are largely
concentrated.
Beyond the central core of p53, the amino end of the gene controls
transcriptional activity of genes downstream of the p53 binding site. In
contrast, the oligomerization function of p53 resides at the carboxy
terminus of the gene, outside the central region prone to frequent
mutation. Oligomerization in the form of dimers and tetramers are
required for DNA binding and transactivation of the protein
(Greenblatt et al., 1994).
In keeping with data in sporadic tumours, the majority of mutations in
Li-Fraumeni pedigrees occur within the central core of the p53 gene;
frequently within highly conserved domains (De Fromental and
Soussi, 1992).
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Although the p53 gene is mutated in at least 13% of sporadic breast
tumours (Prosser et al., 1990), analyses of non Li-Fraumeni pedigrees
in which breast cancer is the predominant malignancy do not
commonly reveal mutations in this gene (Prosser et al., 1991).
Cowden's disease is an autosomal dominant condition producing
multiple hamartomata of skin and oral mucosa (Steel et al., 1991).
Additional organs are involved and perhaps 50% of affected women
develop breast cancer (Brownstein. 1987).
Gorlins syndrome (multiple basal cell carcinoma) is similarly
autosomal dominant. In this syndrome basal cell epitheliomas occur at
young age in association with gynaecological and central nervous
system malignancy. Risk of breast cancer is also increased (Steel et
al., 1991).
Ataxia telangiectasia, transmitted as an autosomal recessive trait, is
associated with an increased risk of development of immunological
malignancy and solid tumours in individuals homozygous for the
disease gene (Hecht and Hecht, 1990). Heterozygotes such as mothers
of affected individuals are also at increased risk of various tumours
(Swift et al., 1990; Borresen et al., 1990). In these individuals the gene
confers a risk of breast cancer three-fold greater than for the general
population (Swift et al., 1987). Recently the gene has been mapped to
the long arm of chromosome 11 (Gatti et al., 1988; Wei et al., 1990;
Ziv et al., 1991).
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It is possible that all these syndromes with which breast cancer is
associated are caused by different genetic events in different
chromosomal regions. The consequence of this would be genetic
heterogeneity of heritable breast cancer. To date, no case of familial
breast cancer in association with a germline microscopic chromosomal
aberration has come to light (Steel et al., 1991). It is evident from the
genetic elucidation of heritable retinoblastoma and FAP however that
continuing examination of constitutional chromosomes in affected
members of breast cancer pedigrees would be worthwhile in order to
localise putative susceptibility genes and avoid the laborious process
of exclusion of large areas of the genome through linkage analysis.
Attempts to locate sites of candidate tumour suppressor genes in
familial breast cancer have involved work on sporadic tumours and
linkage analysis in affected pedigrees. These are reviewed in the final
section.
7. Identification of a Susceptibility Locus for Heritable Breast
Cancer.
a) Cytogenetic Analysis.
Cytogenetic analysis of breast tumours is technically difficult and
yields many abnormalities. Chromosomal rearrangements however do
seem to occur in some regions more frequently than others and at least
twenty-one sites of recurrent breakage have been identified. These are
lp32, 1 p22, 1 p 13, lpll/12, lqll/12, lq21, lq23, lq25, lq32, 2qll,
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2q33, 3p 11/12, 5ql3, 6ql6, 7qll, 8pll, llql3, 12q24, 16q21, 17pll
and 22p and constitute less than 9% of the total genome (Rodgers et
al., 1984; Pathak and Goodacre, 1986; Ferti-Passantonopoulou and
Panani, 1987; Gerbault-Seureau et al., 1987; Mitchell and Santibanez-
Koref, 1990). Precise localisation is only possible at some sites, and
many anomalies defy assignment to specific bands (Steel et al., 1992).
b) Loss of Constitutional Heterozygosity Studies.
A second method by which tumour suppressor gene loci have been
identified through sporadic breast tumour studies involves analysis of
marker alleles in normal somatic and tumour cell DNA from a number
of affected individuals. Most patients will be constitutionally
heterozygous for highly informative polymorphic markers. However
microscopic and sub-microscopic genetic deletion in tumour DNA is a
frequent occurrence and will reveal itself through loss of allele
heterozygosity (apparent homozygosity) at the marker over which the
deletion extends. Background loss of allele heterozygosity is reported
in 5 - 20% of tumours and in this context is without significance (Steel
et al., 1992). Yet when a larger proportion of tumours exhibit loss of
constitutional heterozygosity at a particular locus, there is a suggestion
that this site might be close to a tumour suppressor gene which
requires inactivation for tumour progression (Lasko et al., 1991). The
possibility that localised allele loss in tumour DNA may indicate the
presence of a tumour suppressor gene in close proximity has been
confirmed in studies on retinoblastoma, and also on colorectal cancer
in which a large proportion of tumours exhibited allele loss along the
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long arm of chromosome 5, close to the susceptibility gene for FAP
(Solomon et al., 1987; Vogelstein et al., 1988, Sasaki et al., 1989).
Loss of heterozygosity studies have also yielded information on
tumour suppressor gene loci likely to be involved in early rather than
late tumour development. This approach however relies upon the
ability to distinguish between early and late tumour histology. In
colorectal tumorigenesis, adenomas proceed through well defined
stages prior to development of frank malignancy. Molecular analyses
reveal that events important early in the malignant process include
allele deletion at 5q and ras oncogene mutation. Later events include
loss of heterozygosity at 18q and also 17p close to the p53 gene locus
(Vogelstein et al., 1988). Although this evidence might appear to
exclude p53 as a candidate susceptibility gene for hereditary non
polyposis colorectal cancer, its responsibility for a large proportion of
the Li-Fraumeni cancer family syndrome (to which colorectal
carcinoma does not contribute) is well known. It therefore appears that
single tumour suppressor genes may be important either in the primary
tumorigenic event or at some later stage in tumour progression,
depending on the susceptibility of the tissue type. From a histological
standpoint it is difficult to differentiate early from late cancer of the
breast. Certainly in benign atypical proliferative breast disease, which
is itself a risk factor for breast malignancy, loss of allele
heterozygosity at any locus has yet to be reported (Skolnick et al.,
1990).
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For breast cancer in general there are at least twelve chromosomal
locations in which excessive loss of constitutional heterozygosity
occurs. These involve chromosomes lp, lq, 3p, 6q, 7p, lip, 13q, 16q,
17q, 18q and two regions on 17p (Lasko et al., 1991; Andersen et al.,
1992; Steel et al., 1992). Although the confirmed region of allele loss
on chromosome lp32-36 overlaps a cytogenetically defined break¬
point on the same chromosome arm (lp32), throughout the genome
there is only limited concordance of results from cytogenetic and allele
loss studies (Steel et al, 1992). It is suggested therefore that these two
analytical approaches are of value in defining a multitude of tumour
suppressor genes which have a variety of roles in the tumorigenic
process, either early or late. However their ability to identify candidate
susceptibility loci may be compromised by a great deal of background
noise from other tumour suppressor genes. The large number of such
loci means that only through a combined collaborative approach by
many laboratories would wasteful repetition of work be avoided. In
recent times this has been made possible through the efforts of the
European breast cancer linkage consortium. This consortium of
laboratories has agreed to co-ordinate their activities in the search for a
heritable breast cancer gene. Linkage data on candidate loci are made
available at an early stage to facilitate this process. Loci which appear
to give positive evidence for linkage may then be further examined by
means of joint analysis of pooled family data.
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c) Attempts at Linkage Analysis.
As expected, some attempts at linkage analysis in breast cancer have
centred on those regions in which loss of allele heterozygosity occur in
a high proportion of tumours such as chromosome lp (Genuardi et al.,
1989; Bieche et al., 1990). A maximal LOD score of +1.88 at zero
recombination distance from the polymorphic rhesus blood group was
reported (Ferrell et al., 1989) but this finding was later refuted (King,
1989). Reports of positive linkage at the glutamic-pyruvic
transaminase locus on chromosome 8q (maximal LOD score of +1.95)
(King et al., 1980, 1983) and the ABO blood group locus on
chromosome 9q (maximal LOD score of +1.99) (Skolnick et al.,
1984), have also been challenged (Cannon et al., 1983; Bishop et al.,
1988; Ferrell et al.. 1989). Loss of constitutional heterozygosity at
17p 13, telomeric to the p53 gene locus, has been reported in over 60%
of breast tumours (MacKay et al., 1988; Coles et al., 1990). A LOD
score of +1.8 at this locus (known as YNZ 22.1) was calculated for a
single pedigree with familial breast cancer (MacKay, 1989), although
other centres could not confirm linkage at this site (Hall et al., 1989).
Away from the short arm of chromosome 17, an analysis of linkage in
a series of American pedigrees suggested that a marker known as
CMM86 mapping to the long arm of this chromosome at 17q21 -22
produced a maximal LOD score of +5.98 at zero recombination in
families in which breast cancer tended to occur at a young age (Hall et
al., 1990). LOD scores were markedly positive in six out of seven such
pedigrees. In contrast, linkage was refuted in families where breast
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cancer was diagnosed at an older age, with highly negative scores
reported in ten out of sixteen such pedigrees. Further evidence for the
existence of a gene responsible for familial breast cancer in proximity
to this locus was provided in a French report in which three out of five
large pedigrees with breast and ovarian cancer exhibited strong
evidence in favour of linkage at this locus (Narod at al., 1991). These
studies suggested that heritable breast cancer might be a heterogenous
entity with a particularly high likelihood of a mutated susceptibility
locus on chromosome 17q existing in families in which breast cancer
at young age or ovarian cancer at any age formed part of the
syndrome. The European breast cancer linkage consortium found that
these data were consistent with a range of possible interpretations; at
one extreme, tight linkage of the two loci in only 20% of families, and
at the other, a disease gene located up to 20cM from this marker with
up to 90% of families linked (Easton et al., 1993). As yet there is a
paucity of data from breast tumour loss of heterozygosity studies at
CMM86, but a particularly high degree of allele loss has been found in
sporadic ovarian cancer at CMM86 and regions just telomeric to this
site (Eccles et al., 1990; Russell et al., 1990; Sato et al., 1991; Foulkes
et al., 1991). Loss of heterozygosity at CMM86 is also apparent, but
less markedly so, in sporadic breast tumours (Coles et al., 1990; Cropp
et al., 1990).
A number of candidate genes are known to lie on the long arm of
chromosome 17 (Solomon and Barker, 1989; Hall et al., 1990;
McKusick, 1990). The proteins which they encode include the trans¬
membrane receptor Erb B2 amplified in many primary breast tumours
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(Coussens et al., 1985; Di Fiore et al., 1987), 17 B-oestradiol
dehydrogenase (17HSD) which converts oestrone to oestradiol
(McKusick, 1990), homeobox 2 (hox 2) critical for early development
(Hall et al., 1990), nm23 which is expressed in association with breast
cancer lymph node metastasis (Steeg et al., 1988; Bevilacqua et al.,
1989), the human prohibitin gene which is both anti-proliferatory and
mutated in some sporadic breast tumours (Sato et al., 1992), and INT2
which is homologous with one of the mouse mammary tumour virus
integration site (Rosengard et al., 1989). All of these genes are located
centromeric to CMM86 within bands 17q 12-21.
To determine whether a susceptibility gene for heritable breast cancer
exists at this site and to localise it more precisely, linkage studies
involving markers which span the region 17q 12-21 are required.
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Materials and Methods.
1. Pedigree Collection and Ascertainment.
Patients claiming a strong family history of breast cancer were
referred by interested medical practitioners for inclusion in
epidemiological and genetic research based at the MRC Human
Genetics Unit. Pedigrees were extended as far as possible by
patient interview and details of births, marriages and deaths
confirmed by recourse to registration data. This involved
ascertainment of all first and second degree relatives of the proband
as a minimum requirement. In Edinburgh, capital city of Scotland.
West Register House maintains all Scottish registrations including
certificated cause of death. These are complete from 1855 and
Parish records are available prior to this. Medical genealogists
based at the MRC Human Genetics Unit have unique privileged
access to these valuable documents to enable verification of
pedigree data. Causes of death were ascertained from these
Registrar General for Scotland's records and histological diagnoses
of cancer confirmed from pathological departments and other
hospital sources. Details of thirty seven pedigrees were collected in
this way.
Experience of sib-pair linkage analysis (in which two affected
sisters act as a basic pedigree) suggested that a large number (>50)
of such families would be necessary for significant linkage to be
revealed. Therefore only pedigrees with three or more cases of
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breast cancer in blood lineage were included in the linkage study.
This amounted to a total of fifteen families whose basic pedigrees
are shown in Figure 1. There was no bias towards collection of
pedigrees with other particular types of cancer, although all cancer
cases were recorded together with age at histological diagnosis.
Neither was age of onset of breast malignancy a criterion in the
selection of pedigrees for linkage analysis. Survival data was
collected at the time of pedigree ascertainment for individuals who
developed malignancy.
Two additional breast cancer pedigrees were investigated. The first
was ascertained through a proband who was one of 136 breast
cancer patients who had tumours screened for p53 mutations
(Prosser et al., 1992). This individual was the only one found to
have a mutation in the germline. Her pedigree was discovered to
contain a further two breast cancer cases though no first degree
relative was affected. The second family was ascertained as part of
a study into cancer risk in relatives of osteosarcoma patients (Porter
et al., 1992). Two close relatives were found to have breast cancer
in this pedigree which also fulfilled criteria for Li-Fraumeni cancer




Fifteen Edinburgh breast cancer pedigrees subjected to linkage
analysis.
Br : unilateral breast cancer
Brx2 :bilateral breast cancer
Ov : ovarian cancer
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2. Materials and Suppliers.
Alpha Lab
Plastic disposable transfer pipettes/ pastettes
Amersham
Hybond N nylon membrane
Multiple DNA labelling/random priming kit RPM 1600Y
Applied Biosystems



























Agarose gel electrophoresis tank Model H4






Nucleotides dATP, dCTP, dGTP, dTTP
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Taq 1 restriction endonuclease
Taq 1 restriction enzyme buffer
Taq 1 DNA polymerase
Taq 1 DNA polymerase 10X reaction buffer
Tris base
Cecil




Circulation pump 10 r.p.m. (type 82344)
E-C Apparatus corporation




Fotoprep I Ultraviolet transilluminator
Fuji










































Scotfresh regular paper towels
Scotlab
Eppendorf tubes (1.5ml)







Bovine serum albumin (BSA)
Bromophenol blue
























Ultraviolet transilluminator (U.V. stratalinker 1800)
Transatlantic plastics
Sealing polythene
United States Biochemicals (USB)







3. Buffers and Solutions
Lysis buffer : 0.1M Tris HC1, 20mM NaCl. 1 mM EDTA
Resuspension buffer : lOmM Tris HC1. 150mM NaCl,
lOmM EDTA
T.E. buffer : lOmM Tris HCL (pH7.5), 0.5mM EDTA
Digestion buffer : 50mM Tris base (pH8.5), ImM EDTA.
0.5% TWEEN 20
Running buffer : lOOmM EDTA, 0.25% Bromophenol
blue, 30% sucrose
20X TAE buffer : 484g Tris base, 114.2ml acetic acid,
200ml 0.5M EDTA in 51
Denaturing solution : 5g NaOH (0.5M), 219.15g NaCl (1,5M)
in 2.51
50
Neutralising solution : 292.9g NaCl (2M), 394g Tris base (1M)
in 2.51, add HC1 to pH 5.5
20X SSC buffer 876g NaCl, 441.2g Sodium citrate in 51
0.1X SSC wash :
(high stringency)
50ml 10% sodium pyrophosphate,
25ml 20% SDS, 25ml 20X SSC in 51
0.5X SSC wash : 50ml 10% sodium pyrophosphate,
25ml 20% SDS, 125ml 20X SSC in 51
Quick hybridization
solution :
0.5g BSA, 0.5g PVP, 0.5g Ficoll,
lg SDS, lg sodium pyrophosphate,
250ml 20X SSC, lOOmg denatured
salmon sperm DNA in 11
Prehybridization
solution :
10% SDS, 7% PEG 6000,
lOmg/ml denatured salmon sperm DNA
10X TBE buffer : 1M Tris borate, 20mM EDTA (pH8.3)




4. DNA extraction and Purification.
Relatives considered likely to provide information useful for
linkage or p53 mutation analysis were contacted by letter after
permission was granted by their general practitioners. Twenty-five
ml of blood were donated by venesection in heparinised tubes from
those willing to assist. Lymphocytes from 10ml of blood were
transformed with Epstein Barr virus to create lymphoblastoid cell
lines in accordance with standard procedure (Diehl et al., 1964). In
many instances these provide a renewable source of constitutional
DNA. This procedure was carried out by Dr. C.M. Steel, A. Lennon
and Elizabeth Harvey of the MRC Human Genetics Unit.
Chromosome studies were undertaken on 5ml of blood. Peripheral
blood lymphocytes were stimulated and high resolution banding
performed.
a) Blood
Extraction and purification of DNA from fresh peripheral blood
leukocytes was performed by means of the following method
(Boyum, 1968; Gross-Bellard et al., 1972).
To 10ml whole blood, 8ml lysis buffer, 2ml 20% SDS and 20ml
phenol were added, mixed and centrifuged (3000 rpm for 10
minutes). To the upper aqueous layer, 10 ml 7.5M ammonium
acetate and 40ml isopropylalcohol were added and the solution
frozen at -40°C for 30 minutes. DNA was spooled and dried under
52
vacuum. 10ml resuspension buffer and 100 micrograms RNAase
were added and the solution incubated in a waterbath (37°C for 30
minutes). lOOpl 20% SDS and lmg Proteinase K were added
followed by incubation in a waterbath (37°C for 8 hours). In this
solution was mixed an equal volume of phenol and centrifuged
(3000 rpm for 10 minutes). 5ml phenol and 5ml chloroform ■■: iso
amylalcohol (24:1) were added to the supernatant and centrifuged
(3000 rpm for 10 minutes). To the supernatant 5ml of 7.5M
ammonium acetate and 20ml of 100% ethanol were added and the
mixture frozen at -40°C for 1 hour. DNA was spooled, dried under
vacuum, resuspended in 500pl T.E. buffer and stored at 4°C.
b) Paraffin embedded tissue
In a few cases, archival material embedded in paraffin wax was
utilised to prepare DNA from deceased or inaccessible individuals
(MacDonald and Cohen, 1990). In these instances, care was taken
to define non tumour tissue such as uninvolved lymph node, from
which DNA was then extracted by means of the following protocol:
Blades, tweezers and other equipment were cleaned with xylene
before and between each separate tissue sample mounting. Excess
paraffin was trimmed from the tissue and the block mounted on a
microtome. From one to ten lOjim sections were cut depending on
nuclear density in the section. Sections were lifted into 1.5ml
eppendorf tubes with 1ml xylene, mixed for 30 minutes and
pelleted by centrifugation (14,000 rpm for 30 seconds). Xylene was
53
then removed from each tube with a fine-tipped pastette. A further
lml Xylene was added, mixed, tissue pelleted and xylene removed
as before. 0.5ml 100% ethanol was then added, mixed, tissue
pelleted and ethanol removed and this process was repeated with
the same volume of fresh ethanol. The sample was dried under
vacuum, 200pl digestion buffer and 40|ig Proteinase K were added
and incubated in a 37°C waterbath for 8 hours followed by
centrifugation (14,000 rpm for 30 seconds) and stored at 4°C. The
DNA present in the aqueous layer was of adequate quality for
amplification of genomic fragments by means of polymerase chain
reaction (Mullis and Faloona, 1987; Goudie, 1989).
c) Quantification of extracted DNA.
The amount of DNA extracted by these methods was calculated in
the following way ;
1 OgLl sample was mixed with 740p.l distilled water and pipetted into
a glass spectrophotometer cell. Absorbance of light at 260nm and
280nm was measured. Pure DNA gave a ratio a260/a280 - 1-8- The
amount of DNA (ng/jil) was calculated by multiplying A260 by a
factor of 3750 since absorbance at this wavelength is directly
proportional to DNA concentration.
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5. Allele Data for Linkage Analysis
a) Restriction fragment length polymorphisms (RFLPs).
These mapped genetic markers are DNA fragments inherited as
single copies and which demonstrate allelic variation. Most of the
DNA sequence variations initially identified were due to base pair
changes that created or destroyed a cleavage site for a specific
restriction enzyme, causing a change in length of DNA fragment
(RFLP). A marker locus based on a single such variant will have
only two alleles (a single cleavage site is either absent or present).
This results in limited allele data for linkage analysis purposes
(Nakamura et al., 1987).
i) Variable number of tandem repeats (VNTRs).
In recent years, polymorphisms with highly variable restriction
fragment lengths have been discovered. DNA base sequences of
these hypervariable loci indicate that the restriction fragments
contain variable number of tandem repeats (VNTRs) of a short (11
to 60 base pairs) oligonucleotide sequence. These can be highly
informative in linkage analysis when they exhibit multiple alleles.
YNZ 22.1 and CMM86 are such VNTR markers (Nakamura et al.,
1987, 1988b). Probe YNZ 22.1 denotes locus D17S30 and maps to
chromosome band 17pl3.3. Probe CMM86 denotes locus D17S74
and maps to chromosome bands 17q23 (Solomon and Ledbetter
1991, Hall et al., 1992). YNZ 22.1 is a Bam HI fragment from the
cosmid isolated by a zeta-globin oligonucleotide (MacKay, 1988).
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CMM86 is a Hinf I /Taq I fragment, 1.0 - 3.5kb in size isolated
from the vector pUC18 (Nakamura et al., 1988b).
(ii) DNA digestion.
lOjig genomic DNA, 4)0.1 Taql restriction enzyme buffer and 2jil
(10 units) Taq 1 restriction endonuclease were mixed with distilled
water to volume 40pi and centrifuged (14,000 rpm for 30 seconds),
followed by incubation in a 65°C waterbath for 8 hours and further
brief centrifugation. lOpl running buffer was added to make a final
volume of 50pl.
(iii) Agarose gel electrophoresis. (McDonnel et al., 1977;
Southern, 1979).
The electrophoresis tank was prepared and gel tray made flat by
means of a spirit level. Autoclave tape was applied to both ends of
the tray and a comb inserted with an appropriate number of slots.
4g purified agarose was dissolved in 400ml lx TAE buffer. Flask,
stirrer, agarose and buffer were weighed and the 1% agarose gel
boiled. Distilled water was supplemented to regain the original
weight and the gel cooled to 60°C with stirring. This was then
poured into the electrophoresis tray and trapped air bubbles
immediately removed with a pastette, leaving the gel to set
completely. The autoclave tape was then removed and a sufficient
volume of IX TAE buffer poured into the tank to completely
submerge the gel. The comb was carefully removed and one sample
of digested DNA loaded with running buffer into each well. IX
TAE buffer was circulated through the tank and an ice-box by
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means of a pump. The tank was connected to a D.C. power pack
and run at 60V for 18-24 hours from cathode to anode. One comer
of the gel was marked for later orientation and then immersed in 1
litre IX TAE, to which 50jil lOmg/ml ethidium bromide was added
to a final concentration of 0.5p.g/ ml. The gel in TAE was gently
agitated for 30 minutes, destained with 1 litre distilled water for 10
minutes, placed on a U.V. transilluminator to detect incomplete
digestion of DNA and photographed. DNA in the gel was
denatured by immersion in 1.25 litres denaturing solution with
gentle agitation for 45 minutes. It was then neutralized by
immersion in 1.25 litres neutralizing solution with gentle agitation
for 1 hour.
(iv) Southern blotting. (Southern 1975)
The apparatus was prepared by resting a glass plate (0.5 x 23 x
48cm) on top of a plastic tray (30 x 45cm) containing 2 litres 20X
SSC buffer. Whatman 17MM filter paper was placed on this plate
with both ends immersed in buffer. Whatman 3MM paper was
placed on top of this. Both layers were thoroughly soaked in buffer
and air bubbles removed. The gel was removed from neutralizing
solution and set on top of the 3MM filter paper and cling-film was
used to seal the tray around the gel to prevent evaporation of
buffer. A nylon membrane (Hybond N, Amersham, 20 x 23cm) was
placed directly over the gel and air bubbles removed. Two pieces of
dry 3MM paper were placed over the membrane followed by a
large pile of towels (Kleenex) and then green paper towels. A
heavy weight was applied to compress the apparatus for 8 hours.
57
The position of gel wells were marked on the membrane and a
corner cut for orientation. The layers down to the gel were then
discarded but the remainder of the blotting apparatus was
recovered. The membrane was placed on a clean U.V.
transilluminator and the side opposed to the gel illuminated to
covalently bind DNA to the membrane.
(v) Hybridization.
The membrane was placed between two pieces of nylon filter in a
tray of 1 litre 2X SSC buffer, rolled-up with DNA side outermost
and placed in a glass tube with water-tight stopper. If the probe to
be used was YNZ 22.1, 10ml quick-hybridization solution was
added. If the probe was CMM86, 10ml prehybridization solution
was used. Incubation followed in a rotating drum oven at 65°C for
2 hours.
Labelling of DNA was achieved through the hexamer random
priming method (Jacobsen et al., 1974; Feinberg and Vogelstein,
1983) using a Multiple DNA labelling kit (Amersham RPN
1600Y). 4pi of each unlabelled nucleotide in the kit (dTTP, dGTP
and dATP) was added to 5pi reaction buffer (tris-HCl pH7.8,
50mM MgC12 and lOOmM 2-mercaptoethanol) and 5jil primer
solution (containing nuclease-free bovine serum albumin and
random hexanucleotides). 25ng YNZ 22.1 or 200ng CMM86 was
boiled at 100°C for 10 minutes then added to the above mixture
and centrifuged at 14,000 rpm for 30 seconds. 30jiCi [32P] of
dCTP and 5|ll of kit DNA polymerase 1 (klenow fragment in
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50mM potassium phosphate at pH 6.5, lOmM 2-mercaptoethanol
and 50% glycerol) were also added. The 1.5ml eppendorf tube
containing this mixture was incubated in a lead container immersed
at 37°C for 2 hours. Addition of 20|il lOmg/ml salmon sperm DNA
was then followed by half volume 3M sodium acetate and excess
(250jll1) 100% ethanol and freezing at -40°C for 30 minutes in
order to precipitate the DNA. Depending on which labelled probe
was to be hybridized, one of the following protocols was observed.
For YNZ 22.1, the tube was centrifuged at 14,000 rpm for 30
minutes to pellet the labelled probe and 250|il lOmg/ml denatured
salmon sperm DNA with excess (lOOjil) lOjig/ml denatured human
placental DNA added. The sample was boiled at 100°C for 10
minutes, centrifuged at 14,000 rpm for 30 seconds, pipetted into the
glass bottle containing membrane and quick-hybridizing solution,
and incubated in the rotating drum oven at 65°C for 8 hours.
Excess solution from the glass bottle was discarded and 200pl high
stringency 0. IX SSC wash solution poured in to half fill the bottle
which was returned to the oven at 65°C for 10 minutes. The
solution was again discarded and fresh high-stringency wash added
twice more, returning to the oven after each cycle. Finally the
membrane was washed in 0.1X SSC buffer by gentle agitation
again at 65°C for 10 minutes.
For CMM86, the tube was centrifuged at 14,000 rpm for 30
minutes to pellet the labelled probe and resuspended in lOOpl
lOmg/ml denatured human placental DNA, 125pl 20X SSC and
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175JJ.1 distilled water. The sample was boiled at 100°C for 5
minutes and centrifuged again. The pre-hybridization solution from
the glass bottle was discarded and 10ml fresh prehybridization
solution and labelled precipitated probe added by pipette followed
by incubation in the rotating drum oven at 65°C for 8 hours.
Prehybridization solution was then discarded and 200ml 2X SSC
poured in to half fill the bottle followed by gentle agitation at room
temperature for 20 minutes. This solution was discarded and 200ml
2X SSC plus 0.5ml 20% SDS added and gently agitated at room
temperature for 20 minutes. Finally the solution was again
discarded and the membrane washed in 200ml 0.1X SSC plus
0.5ml 20% SDS with gentle agitation again at 65°C for 30 minutes.
Whichever probe was hybridized, the labelled membrane was dried
between two pieces of filter paper and wrapped in cling-film
opposed to a clean, dry Whatman 3MM filter paper of same size
with excess air removed from the package. Pre-flashed X-AR
Kodak Omat film was placed opposed to the DNA side of the
membrane in an X-ray cassette at -70°C for 8 hours and developed
in a RGII Fuji X-ray film processor. The labelled membrane was
then left with a fresh pre-flashed film for a longer period at -70°C
and developed in the same way to reveal fainter bands.
The membrane was cleaned of labelled probe by placing it in
400ml of boiling 0.1% SDS and allowing the solution to cool
immediately. It was then stored in a sealed polythene bag at 4°C for
repeat hybridization if required.
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b) Microsatellites. (Emery and Rimoin, 1990)
There are up to 100,000 hypervariable length polymorphisms
known as microsatellites which are very short sequence elements
of the form (dCdA)n (dGdT)n interspersed throughout the human
genome and are estimated to occur every 30 - 60 kilobases
(Miesfield et al., 1981; Weber and May, 1989). Polymerase chain
reaction (Mullis and Faloona, 1987) using single copy primers
flanking the CA repeat microsatellite is necessary to demonstrate
the length differences which are multiples of two base pairs.
(i) Primer Preparation
Oligonucleotide primers were produced by Agnes Gallacher of the
MRC Human Genetics Unit in DNA synthesisers (Applied
Biosystems 381A and 391A) and stored in 350jll1 8M ammonium
hydroxide at concentration lmg/ml. Primers were precipitated by
addition of 35pl 3M sodium acetate and 5|il 100% ethanol
followed by freezing at -20°C for 30 minutes. Samples were then
spun at 14,000 rpm for 30 seconds and the pellet washed twice in
lml 100% ethanol by inversion. Following another brief spin the
sample was dried over vacuum and stored in 200|il T.E. buffer.
(ii) Microsatellite Amplification.
The microsatellites for amplification were nm23 at position
17q21.3-22, 42D6 (D17S588) at 17q21 MFD188 (D17S579) at
position 17q 12-21 (Hall et al, 1992). For females these are
reported as being 11, 18 and 28 cM centromeric to D17S74
respectively (the CMM86 locus). For males these are 4, 7 and 12
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cM centromeric to this locus (Easton et al., 1993). These distances
are illustrated in Figure 3.
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Figure 3
Chromosome 17 frame indicating recombination distances between
markers CMM86, NM23, 42D6 and MFD 188 in males and females






















The process of microsatellite amplification involved mixing of
lOOng genomic DNA with 50pmoles of each primer, 25jil (2mM)
of each dATP, dGTP, dTTP and dCTP (Boehringer Mannheim),
0.75U Taql polymerase and 5|il Taq 1 polymerase 10X reaction
buffer (both from Promega Ltd, UK) to make a reaction volume of
50pl 2 drops of light mineral oil were laid onto each sample to
prevent evaporation during temperature cycling. From this sample,
nm23 was amplified using primer sequences TTG ACC GGG GTA
GAG AAC TC and TCT CAG TAC TTC CCG TGA CC. 42D6 was
amplified using primer sequences CCT GGT CTA GGA AGA
GTG TCA and GTG TAA GCA TCT GTG TAT ACT AC.
MFD 188 was amplified using primer sequences AGT CCT GTA
GAC AAA ACC TG and CAG TTT CAT ACC AAG TTC CT.
Amplification was achieved by means of automated thermocyclers
(Biometra TRIO-thermoblock). For both nm23 and MFD 188 PCR
conditions were 94°C 5 minutes followed by 30 cycles of 94°C 1
minute, 55°C 1 minute and 72°C 1 minute with a final 5 minute
extension at 72°C. Conditions for 42D6 were 27 cycles of 94°C 30
seconds, 55°C 30 seconds and 72°C 1 minute.
To determine whether PCR amplification had been successfully
achieved, a 2% agarose gel of volume 100ml was made (2g purified
agarose in 100ml lx TAE buffer) and allowed to set in a small gel
tray (11 x 14cm). lOjil of amplified PCR product with 2.5jil
running buffer were loaded into each well. The tray was immersed
in a solution of IX TAE buffer containing 25pl lOmg/ml ethidium
bromide and run at 100V for 90 minutes. After de-staining with
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500ml distilled water, a U.V. transilluminator (UVP inc.) was
employed to identify amplified microsatellite fragments migrating
from cathode to anode.
(iii) Polyacrylamide gel electrophoresis.
Polymorphisms in microsatellite markers of different lengths were
separated by means of polyacrylamide gel electrophoresis for
which the following method was used
Glass plates (30 x 30cm) were successively cleaned in detergent,
tap water and distilled water. The inside surface of each plate was
washed with 100% ethanol, dried and coated with
dimethyldichlorosilane solution to endow water-repellent
properties. The two inside surfaces were opposed but separated by
0.75mm with spacers. The edges of the two plates were sealed
firmly together with autoclave tape. The apparatus was plugged at
the base by 6ml of 10% acrylamide mixture containing 1.25ml 40%
acrylamide, 4.75ml distilled water, lmg ammonium persulphate
and 12|il TEMED (N,N,N',N', tetramethylethylenediamine). A 10%
acrylamide solution with denaturant properties was made by
mixing 37.5ml 40% acrylamide and 54g urea with 7.5ml 20X TBE
buffer and adding distilled water to a final volume of 150ml. After
addition of 25mg ammonium persulphate and 150|il TEMED this
mixture was poured between the plates and a comb inserted by the
straight edge into the solution which was left for 30 minutes until
polymerisation. The comb and tape were then removed and after
washing in distilled water and IX TBE buffer, the comb was re-
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inserted with teeth into the gel. The glass plates sandwiching the
gel were then placed in an electrophoresis tank (Bethesda Research
Laboratories Life Technologies inc., model S2) and clampled
together. 500ml IX TBE was poured in to each of the upper and
lower tank reservoirs. The comb was removed from the gel and the
wells washed in IX TBE buffer.
PCR products were prepared by mixing 14jll1 sample with 8pl stop
buffer, heated at 80°C for 3 minutes and cooled on ice. The
samples were loaded and the gel run at 1500 - 1900V, 30 - 45mA
(60W) until bromophenol blue dye from the stop buffer ran out of
the gel (approx. 3 hours). The gel was then soaked in 500ml
solution of 10 - 12% methanol and 10% glacial acetic acid for 2
hours. This process was repeated using fresh solutions. The gel was
dried in an oven at 70°C for 8 hours and cooled to room
temperature.
(iv) DNA electroblotting and hybridization with radiolabeled
(dCdA) probe
DNA fragments were transferred from the relevant part of the gel to
the nylon blotting membrane, Hybond N (Amersham International
pic.) by means of standard electroblotting procedures (Stellwag and
Dahlberg, 1980). Hybridization of CA repeat elements on the
membrane to a radio-labelled (CA)ll repeat probe was achieved
and photographed in the standard way (Cohen et al., 1992)
Electroblotting, hybridization and autoradiography were carried out
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by Dr Brian Cohen and Mairi Wallace at the MRC Human Genetics
Unit.
6. p53 Mutation Analysis.
(a) Denaturing gradient gel electrophoresis (DGGE). (Fisher and
Lerman, 1983)
Germline mutations in the normal wild-type sequence of the p53
gene such as small base pair substitutions can be responsible for
malignant predisposition (Soussi and De Fromental, 1992). These
changes can be detected by Denaturing Gradient Gel
Electrophoresis (DGGE). The DGGE separation technique relies on
the fact that strand dissociation of amplified DNA fragments in
discrete sequence-dependent melting domains cause an abrupt
decrease in mobility visible on an acrylamide gel containing a
gradient of denaturant (Borresen et al., 1991). After PCR
amplification up to four fragments appear in lanes in which a single
base pair mismatch resulting from a mutation in the p53 gene
produces two homoduplexes (wild-type double strand and mutant
double strand) and two heteroduplexes (the two different
arrangements of mutant and wild-type DNA in double strand
formation) (Erlich, 1989).
i) Primer preparation.
Oligonucleotide primers were produced in the same way as
described in section 5 (b) (i)
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(ii) Exon amplification
Primer sequences were manufactured which would enable
amplification of the highly conserved domains of exons 5, 7 and 8
of the p53 gene (Borresen et al., 1991). The codons covered by four
sets of primers are responsible for 20 of the 25 reports of germ-line
p53 mutations published to date (Santibanez-Koref et al., 1991a,
1991b; De Fromental and Soussi, 1992; Prosser et al., 1992;
Iavarone et al., 1992; Sidransky et al., 1992b).
GC clamps were attached to primers (Erlich, 1989). Primer
sequences TTC CTC TTC CTG CAG TAC TC and CGC CCG
CCG CGC CCC GCG CCC GTC CCG CCG CCC CCG CCC GTG
GCG CGG ACG CGG GTG CCG amplified codons 128 - 153 of
exon 5. Sequences CGC CCG CCG CGC CCC GCG CCC GTC
CCG CCG CCC CCG CCC GTT CCA CAC CCC CGC CCG GCA
and GCC CCA GCT GCT CAC CAT CG amplified codons 155 -
185 of exon 5. Sequences CAC CAT CCA CTA CAA CTA CA
and GCG GGC GGC GCG GGG CGC GGG CAG GGC GGC
GGG GGC GGG CAG TCT TCC AGT GTG ATG ATG amplified
codons 237 - 253 of exon 7. Sequences ATC CTG AGT AGT GGT
AAT CT and GCG GGC GGC GCG GGG CGC GGG CAG GGC
GGC GGG GGC GGG CTA CCT CGC TTA GTG CTC CCT
amplified codons 265 - 301 of exon 8. Blood lymphocyte
DNA from subjects under analysis were mixed with primer pairs,
nucleotides, Taq 1 polymerase and buffer as described in section
5(b)(ii). PCR conditions were 94°C for 7 minutes followed by 35
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cycles of 94°C for 45 seconds, 55°C for 45 seconds and 72°C for
45 seconds and ended with a final 10 minute extension at 72°C.
(iii) Polyacrylamide gel electrophoresis and staining.
Perpendicular gradient denaturing gels (18 x 15 x 0.1cm)
containing TEMED (lOpl/gel), ammonium persulphate (5mg/gel)
and a 10% acrylamide solution in lx TBE buffer were cast with a
2-channel pump mixing 80% denaturant solution into 20% solution
to create a 30 - 80% denaturant gradient (100% denaturant
corresponds to 7M urea and 40% formamide. PCR products were
loaded into wells along the top of the gel and run across 80V with
the electrophoresis direction parallel to the denaturant gradient.
Gels were submerged in IX TBE buffer at 56°C in a self-
constructed cell based on protocol criteria developed by Borresen
et ai, (1991). These modifications allowed the glass plates
surrounding the gels to be in direct contact with the buffer on both
sides. Extensive circulation of buffer was provided during the runs.
Running time was 2-3 hours. After electrophoresis, the gels were
stained in ethidium bromide (2mg/l TBE) and photographed using
a U.V. transilluminator.
b) Sequencing.
The polymerised samples which produced from two to four bands
on DGGE (indicating non-identical p53 strands) were cut-out of the
gel. Each excised band was melted and DNA sequenced using
dideoxynucleotide labelling within the sequenase DNA sequencing
kit and run on a gradient denaturing gel which was radiolabelled
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and autoradiographed. Sequencing was performed by Dr Brian
Cohen and Mairi Wallace of the MRC Human Genetics Unit.
7. Linkage analysis.
We have used the program for pedigree analysis MENDEL (Lange
et al., 1988). Within this program we have utilised the segregation
analysis model determined by Iselius et al., (1991) in which 1248
nuclear families with breast cancer were collected from two British
series. This contrasts with the Cancer and Steroid Hormone Study
(CASH) analysis by Claus et al., (1991) in which four times this
number of nuclear families were utilised, but from centres only in
the U.S.A. In the British model the estimate of gene frequency is
0.003 with lifetime penetrance of 0.83 compared with 0.92 in the
CASH study. In place of liability classes of risk of breast cancer by
age-group, mathematical formulae were inserted into the program.
These formulae described best-fit curves for breast cancer risk
by age for gene carriers and non-gene carriers as estimated by
Iselius et al., (1991).
For female (carriers) heterozygotes:
Probability ( T < t) = 0.9
1 + [35 /t-15] 3
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For female (non-carriers) homozygotes:
Probability ( T < t) = 04
1 + [ 50 / t-15 ] 4
t = age of individual
Probability (T < t) = probability of developing breast cancer prior
to age t.
In tabulated form these equations produce estimates for probability
of developing breast cancer which are illustrated below :












For the purpose of the model, male breast cancer at any age was
defined as having an incidence of 1% that of female breast cancer
at the same age, but otherwise followed the same age incidence
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curves as female breast cancer (Lynch and Kullander, 1987a). In a
separate analysis the above conditions were maintained but in
addition ovarian cancer at any age was defined as endowing the
patient with a likelihood of carrying the gene equivalent to that for
female breast cancer at age 25, with and without a similar
assumption about ovarian cancer. The model requires an estimate
of the probabilty that an affected individual is either a gene carrier
or non-gene carrier. The probability estimates of Iselius et al.,
(1991) are utalised in this programme. Thus an affected individual
belonging to a low risk liability class (an older woman) is less
likely to have the putative breast cancer gene than an affected
individual in a high-risk liability class (a younger woman). The
probability of an affected individual being a gene carrier is
tabulated below :
Age Probability of affected individual being a gene carrier.
20-24 0.897







Observations on allele segregation in cases of colon cancer and
other malignancies were made in order to investigate the possibility
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of linkage to a breast cancer gene in these diseases also. The
analysis required an estimate of population frequency of alleles for
each polymorphic marker analysed. These were determined from
DNA analysis of spouses of breast cancer family members. These
non-blood relatives provided upwards of 132 individuals from
which population allele frequencies were estimated. Relative allele
frequencies of all markers investigated are illustrated in Table I.
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Table I
Population of allele frequencies for YNZ22.1, CMM86, NM23,
42D6 and MFD 188.
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Table I
Allele Relative Frequency of Alleles (%)
Number YNZ22.1 CMM86 NM23 42D6 MFD188
1 10.6 1.5 35.9 2.0 0.7
2 11.4 7.2 9.0 8.7 2.1
3 20.5 31.9 12.4 2.0 4.8
4 30.3 18.8 22.5 0.7 6.9
5 17.4 6.5 20.2 1.7 15.9
6 5.3 5.8 1.7 22.0
7 4.5 13.0 14.1 14.5
8 11.6 8.1 4.2
9 1.5 11.4 6.2
10 2.2 19.5 4.1
11 24.1 12.4
12 6.0 6.2
Total 100.0 100.0 100.0 100.0 100.0
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8. Structural Chromosome Analysis.
Blood samples were obtained by venesection from both affected
and unaffected relatives. Chromosome studies were undertaken on
5ml blood. 0.8ml aliquots of whole blood were cultured in a variety
of different media including DF10 (a low folate medium for
expression of folate sensitive fragile sites) and RPMI 1640 Dutch
modification using thymidine (4 x 10~7m) for thymidylate stress.
All cultures were supplemented with 10% foetal calf serum,
penicillin and streptomycin. Lymphocytes were stimulated with
phytohaemagluttinin and high resolution banding was carried out
by synchronisation of cell division in culture with either
bromodeoxyuridine, or methotrexate and harvest of the cells 5
hours after the release of the block and arrest of the cells with
colcemid (lpg/ml) for 10 minutes (Yunis, 1976). At least 10 nuclei
were analysed from each individual. This laboratory work was
carried out by Dr G. Spowart and H. Morrison of the MRC Human
Genetics Unit. Quantitative differences in the proportion of cells
with rearrangements could be compared in individuals who were
identified as either carriers or non carriers of a 17q breast cancer




1. p53 mutation analysis in breast cancer families.
2. Linkage analysis.
i) Two point LOD scores.
ii) Identification of probable 17q breast cancer gene carriers.
iii) Penetrance, age-incidence and survival in 17q breast cancer
gene carriers.
3. Structural chromosome analysis.
Results
1. p53 mutation analysis in breast cancer families.
A number of individuals in two breast cancer pedigrees illustrated in
Figure 2 were screened for germline p53 mutation. By means of
DGGE and gene sequencing, three individuals in pedigree A were
shown to exhibit an exon 8 mutation at codon 267 in one copy of p53;
CGG to CAG thereby replacing arginine with glutamine (Prosser et
al, 1992). The mutation lies in the general region of previously
reported mutations (De Fromental and Soussi, 1992). More
specifically it is situated between two evolutionarily conserved zones
within an arginine codon invariant in all species studied (Prosser et
al., 1992). From analysis of pedigree A it can be inferred that all
breast cancer cases and in addition the individual with lung and
cervical cancer must also have inherited this mutation. Three
individuals in pedigree A were screened and found to have only wild
types p53 copies. One further distant relative not illustrated in
pedigree A who developed a primary brain tumour aged 35 was also
found to have wild type p53. He was, however, separated from the
closest cancer case in pedigree A by four generations.
DGGE and gene sequencing in members of pedigree B have revealed
a germline exon 8 mutation at codon 273 of the p53 gene (CGT to
CAT; arginine to histidine) in a deceased individual diagnosed with
breast cancer at age 33 and in her daughter with osteosarcoma at age
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17. Two unaffected brothers of the proband were found to have wild
type germline p53.
2. Linkage analysis
i) Two point LOD scores :
Table II records the total number of affected individuals with breast or
ovarian cancer in pedigrees typed at markers located on chromosome
17. The number of individuals for whom lymphocyte DNA or
paraffin-wax embedded material was utilised for genotyping is also
shown, together with typing success rates.
17p analysis :
Table III records LOD scores at YNZ 22.1 in 5 breast cancer
pedigrees.
17q analysis :
Two point LOD scores for separate markers on chromosome 17q are
recorded in Tables IV, V, VI and VII. Pedigrees are ranked according
to average age of onset of breast cancer in the family. Scores in this
analysis are calculated via a model which assumes that the disease-
associated gene causes breast cancer alone; both unilateral and
bilateral disease are assumed to follow the standard model age-
incidence curves predicted by segregation analysis studies.
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Table II
Number of cases of unilateral and bilateral breast cancer and
ovarian cancer in 15 Edinburgh pedigrees subjected to linkage
analysis- Number of blood and wax-section DNA samples
available and number of individuals successfully typed at one or
























































































































































Table III - VII
Two-point LOD scores at separate markers on chromosome 17
under assumption that all breast cancer conforms to model curves.
Table III: YNZ22.1
Table IV: CMM86
Table V : NM23
Table VI : 42D6









































































































































































































































































































































































































































































































































































Five families were typed at CMM86. Haplotyping at this locus was
limited due to difficulties with hybridisation. As a result, only one
pedigree could be considered informative at this locus and the
pedigree did not exhibit tight linkage to a gene in close proximity
(Table IV). Analysis of allele data from 7 families at NM23 was again
largely uninformative, but a positive LOD score in one pedigree
suggested that the susceptibility gene might be closer to this locus
(Table V). Typing at 42D6 and MFD 188 however seemed to provide
the greatest evidence for linkage (Tables VI and VII). Therefore most
effort was expended in typing alleles at these loci in all available
pedigrees. Pedigrees 3 and 33 were omitted from analysis at locus
MFD 188, due to an inadequate quantity of DNA available for typing
from crucial individuals.
Tables VIII, IX and X record LOD scores at the tightly linked markers
42D6 and MFD 188 only. On examination of allele segregation within
Edinburgh pedigrees, it was apparent that all alleles typed at 42D6 and
MFD 188 in cases of bilateral breast cancer and ovarian cancer also
segregated with other breast cancer or other ovarian cancer cases in
the same pedigree. Therefore, in consequence of a high probability of
carrier status in bilateral breast cancer and ovarian cancer cases
(Easton et al., 1993), scores in Table VIII assume that bilateral breast
cancer at any age has endowed the patient with a likelihood of
carrying the gene equivalent to that for breast cancer at age 25. This
affects LOD scores in 8 out of 15 pedigrees. Scores in Table IX
assume that ovarian cancer at any age is equivalent to breast cancer at
age 25 with both bilateral and unilateral breast cancer made to
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conform to standard model age-incidence curves. This affects LOD
scores in 8 out of 15 pedigrees. Scores in Table X assume that both
ovarian and bilateral breast disease at any age are equivalent to breast
cancer at age 25. Figure 4 records summated 2-point LOD scores from
Table X in graphic form.
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Tables VIII -» X
Two-point LOD scores at a) 42D6 and b) MFD 188 under





bilateral disease endows the individual
with a likelihood of carrying the gene
equivalent to that for unilateral breast
cancer at age 25.
ovarian cancer at any age endows a risk
of carrying the gene equivalent to that
for unilateral breast cancer at age 25.
either bilateral breast cancer or ovarian
cancer at any age endows a risk of
carrying the gene equivalent to that for



























































































































































































































































































































































































































































































































































Summated two-point LOD scores from Table X at markers 42D6
and MFD 188 for varying genetic distances from the susceptibility




An examination of allele segregation with colon cancer was also
made. There were 13 cases of colon cancer in the 15 pedigrees. Allele
data from these revealed that alleles in 9 colon cancer cases segregated
elsewhere in the pedigree with breast cancer whereas in 4 they did not
co-segregate in this way. A similar study of allele segregation with
other cancers (non-breast, non-ovarian and non-colon) was performed.
In other cancers diagnosed under age 50, alleles in 13 out of 17
individuals co-segregated with breast cancer. In 44 other cancer cases
diagnosed at any age, alleles in 31 individuals co-segregated with
breast malignancy compared with those in 13 which did not.
Meiotic recombination of marker alleles occurs with a frequency
related to (though in non-linear fashion) the physical distance between
markers. We observed recombination between markers in some
Edinburgh pedigrees in which disease and 17q markers appear to be
linked. At the point of recombination it was possible to identify alleles
of markers which failed to segregate with the disease and appeared to
be abandoned by the disease phenotype in subsequent generations. If
it is also assumed that there is a low frequency of double
recombination between markers and a negligible chance of sporadic
breast cancer cases in the pedigree, then the chromosomal arm
between and beyond these abandoned marker alleles can be excluded
as a likely site for the breast cancer gene. This allows a recombination
exclusion map to be produced in which each such recombination
results in the exclusion of part of chromosome 17q as a candidate site.
This is illustrated in Figure 5 by arrows placed on a chromosome 17q
frame. Each arrow denotes a sinale recombination event which
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excludes the region covered by the arrow. Only families which appear
likely to be linked to a 17q gene are included in this map. Ideotypes of
the 5 Edinburgh pedigrees with these critical recombinants are
illustrated in Figures 6a and 6b. Haplotypes of all other Edinburgh
pedigrees at loci 42D6 and MFD 188 are illustrated in Figures 6c, 6d
and 6e. Diagnoses of all cancers, together with age at diagnosis are
recorded in Table XI with individuals identified in relation to
identification numbers shown in figures 6a - 6e.
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Figure 5
Recombination exclusion map of chromosome 17q. Each arrow
denotes a presumed gene carrier in which a meiotic recombination
in a marker allele causes failure of the allele to segregate with
breast cancer. The arrow covers the part of chromosome 17q which
is excluded as a site of the gene. Pedigrees which contain these
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Figures 6a - 6e
Fifteen Edinburgh pedigrees with identification numbers of
individuals with cancer recorded in detail in Table XI. Haplotypes
at 17q markers illustrated. Linked haplotypes are typed in bold.
Figures 6a, 6b : Ideotypes of 5 Edinburgh pedigrees
illustrating critical recombinants which are
arrowed. Position of critical recombinants
which may exist in pedigree EDIN 11
impossible to localise.
Figures 6c, 6d, 6e : Ideotypes of remaining 10 Edinburgh
pedigrees illustrating haplotypes at loci
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Table XI
All diagnoses of cancer with age of diagnosis in 15 Edinburgh
pedigrees. Ranking by family and individual identifier as




Irlpnfifier Cnnrnr AOP Fnmilv trtenfifier Canrpr A or
1 1 Gastric 65 27 1 Breast 68
1 2 Breast x2 33 27 2 Lung 70
1 3 Breast x2 43 27 3 Breast 46
1 4 Breast x2 46 Lung, Colon 51
Ovarian 67 27 4 Breast 73
1 5 Breast 68 27 5 Uterus 65
Stomach 57 27 6 Lung 79
1 6 Breast 33 27 Leukaemia 79
1 7 FAP 33 27 7 Breast 71
Breast x2 31 27 8 Breast 43
1 8 Breast 35 27 9 Breast 58
1 9 Breast 42 27 10 Breast 43
1 10 Cervix 05 29 1 Prostate 60
2 1 Oesoohaaus 54 29 2 Colon 63
2 2 Colon 64 Squam. Skin 75
0 3 Breast x2 54 29 3 Breast 67
2 4 Breast x2 54 29 4 Breast 43
0 5 Breast 47 29 5 Breast 48
Ovarian 51 29 6 Breast 44
2 6 CNS Tumour 66 30 1 Breast 72
2 7 Breast x2 37 30 a Breast x2 62
Lung 63 30 3 Breast 53
2 8 Colon 75 30 4 Breast 60
-> 9 Breast 52 30 5 Breast 43
2 10 Breast 39 33 1 Breast 53
Ovarian 40 33 a Breast 42
2 11 Squam. Anus 37 33 3 Breast 42
2 12 Breast 40 37 1 Ovarian 63
Ovarian 45 37 a Lung 66
o 1 Breast 62 37 .5 Breast 34
3 2 Breast 52 37 4 Breast 38
3 3 Breast x2 44 37 5 Breast x2 41
3 4 Breast 45 37 6 Breast x2 35
11 I Breast 65 Ovarian 46
1 | 2 Breast 37 37 7 Breast x2 33
1 i 3 Breast 35 38 1 Lune 70
1 1 4 Prostate 74 38 a Breast 48
1 1 5 Breast 66 38 3 Breast 44
1 1 6 Renal 54 38 4 Breast 42
1 l 7 Mvxonta 68 84 1 Colon 67
1 1 8 Breast 36 84 a Colon 69
1 1 9 Breast 42 84 3 Lymphoma 69
1 1 10 Fibrosarcoma 25 84 4 Breast 71
1 I 1 1 Breast 44 84 5 Breast 52
1 1 12 Leukaemia 47 84 6 Breast 59
1 1 13 Breast 22 84 7 Colon 49
12 ! Luna 65 1021 1 Sarcoma 52
12 2 Breast 77 1021 2 Colon 42
12 3 Breast 48 1021 3 Bladder 69
12 4 Basal Cell Ca 49 1021 4 Breast 67
12 5 Breast 52 1021 5 Bladder 81
12 6 Breast 30 1021 6 Breast 65
12 7 PNS Tumour 25 1021 7 Ovarian 60
12 8 Breast 37 Colon 60
12 9 Cervix 38 1021 8 Breast x2 47
16 1 Sarcoma 39 1021 9 Luna 64
16 2 Prostate 80 1021 10 Luna 68
16 3 Breast x2 54 2000 1 Breast ??
16 4 Breast 61 2000 2 Ovarian 60
16 5 Breast 31 2000 3 Ovarian 54
16 6 Breast 33 2000 4 Ovarian 40
Lung 52 2000 5 Breast 36
16 7 Breast 48 2000 6 Breast x2 48
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ii) Identification of probable 17q breast cancer gene carriers :
The probability that any family member has breast cancer as a result
of inheritance of a gene on 17q is classically determined through the
expression of final, or posterior, probability via initial calculation of
prior and conditional probabilities in accordance with Bayes' theorem
(Emery, 1986). Linkage analysis provides the conditional probability
data. The prior probability that breast-ovarian cancer pedigrees are
linked to 17q is conservatively estimated as 75%, compared with 50%
for breast cancer pedigrees (Easton et al,, 1993). Thus the posterior
probability of linkage to 17q can be calculated for each of 15 breast
cancer pedigrees according to the equation :
Posterior probability in favour of linkage =
f Prior probability in favour x Conditional probability in favour]
Prior probability x Conditional probability + Prior probability x Conditional probability
in favour in favour against against
Figure 7 illustrates maximal posterior probability of linkage to the 17q
breast cancer gene at either 42D6 of MFD 188 for each of 15 breast
cancer pedigrees. 10 families were considered to be "site-specific"
cancer families (no cases of ovarian cancer) and 5 were "breast-
ovarian" cancer families (at least one case of ovarian cancer). In a
single hypothetical pedigree, a posterior probability of linkage of 75%
indicates that the probability that a mutant susceptibility gene close to
markers analysed has caused disease in the family is three times more
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likely than not. Arbitrarily, therefore, it might be considered that
pedigrees with posterior probability of linkage greater than 75% could
be viewed as being "probably" linked to the disease-associated gene. 8
out of 15 pedigrees exhibited maximal posterior probabilities of
linkage greater than 75% (79.2%, 85.5%, 88.8%, 92.3%, 94.6%,
95.9%, 99.2% and 99.9%). Individuals within these linked families for
whom typing at 42D6 and MFD 188 suggested they had inherited the
marker alleles associated elsewhere in the pedigree with malignancy
were identified as probable carriers of the 17q cancer susceptibility
gene mutation. Probable non-carriers were identified from among their
relatives in a similar fashion. Figure 8 indicates how marker data in a
linked pedigree is able to reveal relatives likely to be either carriers or
non-carriers of the mutated susceptibility gene. This gene has been
assigned the nomenclature BRCA I ( BReast CAncer I ) by the Human
Genome Mapping Project.
Figure 7
Posterior probability of linkage (%) in Edinburgh pedigrees
identified by number and calculated on the basis of prior and
conditional odds from 17q marker data. Posterior odds illustrated
are derived from whichever single polymorphism (either 42D6 or
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Figure 8
Edinburgh pedigree EDIN 2000 with probability of linkage to
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iii) Penetrance, age-incidence and survival in 17q breast
cancer gene carriers.
A total of 102 female relatives from the 8 linked pedigrees were typed
in sufficient detail to determine their probable carrier status. 61
women were classified as probable BRCA I mutation carriers; 22 of
these had been diagnosed with unilateral breast cancer and 13 with
bilateral disease. Date of breast cancer diagnosis was recorded as date
of histological confirmation. Mean age of first breast cancer in this
group was 43.4 years (standard error 1.7 years). Median year of first
diagnosis was 1974 (range 1942 - 1992). 41 women were probable
non-carriers of BRCA I mutation (Figure 9).
Genetic penetrance of the gene in BRCA1-linked pedigrees was
determined by analysis of the proportion of affected and unaffected
BRCA I mutation carriers at given age-intervals. The resultant BRCA
I mutation penetrance function is shown in graphic form in Figure 10.
For comparison, the segregation analysis penetrance function of a
gene responsible for the totality of heritable breast cancer, as
calculated by Iselius et al (1991) is also illustrated. The proportion of
BRCA I mutation carriers diagnosed with breast cancer was 15% by
age 35, 46% by age 45 and 88% by age 65.
The cumulative age-incidence curve for BRCA I mutation carriers is
shown graphically in Figure 11 together with a Scottish population
curve for comparison from the period 1971 - 1973 (Cancer
Registration and Survival Statistics Scotland, 1981). Over 90% of
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breast cancer diagnoses and deaths within the 61 BRCA I mutation
carriers occurred in Scotland. 60% of the total first diagnosis of breast
cancer occurred by age 45 and, in this cohort, 100% by age 65.
Figure 9
Venn diagram illustrating number of individuals with breast or
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Figure 10
Cumulative age-specific breast cancer penetrance in BRCA1
mutation carriers and, for comparison, penetrance calculated in
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The survival curve for BRCA I mutation carriers with breast cancer is
illustrated in Figure 12. 5, 10 and 20 year survival rates were 83%
(24/29 individuals), 63% (15/24) and 41% (9/22) respectively.
Population tables revealed that 5 year survival in an age-matched
group of 910 Scottish patients with breast cancer diagnosed during the
period 1971 - 1973 was 61.1% (Cancer Registration and Survival
Statistics Scotland, 1981). This figure is significantly different from
the 83% 5 year survival rate in BRCA I mutation carriers (X2 = 4.70, p
< 0.05). Survival data were also examined in 24 individuals with
breast cancer from 7 pedigrees not obviously linked to 17q 12-21
(posterior odds of linkage ranged from 41.4% to 63.5%). In this group
5 year survival was 59% (10 out of 17 individuals). In contrast to the
findings in carriers of BRCA I mutation there was no significant
difference between this figure and expected survival taken from age-
matched Scottish cancer registration data (also 59%).
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Figure 12
Cumulative overall survival since first diagnosis of breast cancer in
BRCA1 mutation carriers (median year of diagnosis 1974). Five
year survival in an age-matched Scottish population is also shown
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3. Structural chromosome analysis.
Peripheral blood lymphocytes were karyotyped in 104 blood relatives
in 18 pedigrees which contained at least two individuals with breast
cancer. 16 pedigrees had a low frequency of constitutional
chromosome rearrangements (Table Xlla). In these families, 7
separate mosaicism involving 6individuals were found. 6 of these
involved mosaicism for a 45X cell line. In addition there were 3
constitutional variants. No evidence for co-segregation of the same
anomalies in other family members was observed. No individual with
mosaicism or variant had obvious developmental defects.
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Table Xlla
Details of individuals in which 100 cells were examined exhibiting
a) constitutional chromosomal variants and
b) chromosomal mosaicisms in the 14 Edinburgh pedigrees which









Unaffected age 41 from a family
not showing linkage to 17q
46XY
22s+
Unaffected age 73 from a family
not showing linkage to 17q
46XX
21 s+





Ca breast age 45, venesection age 47.
Pedigree odds of 17q linkage = 79.2%
45X/ 7/100
46XX 93/100
Ca breast age 42, venesection age 51




Unaffected age 56, venesection age 54.
Carrier of 17q susceptibility gene :




Unaffected at age 55, venesection age 55.
Non-carrier of 17q susceptibility gene :
Pedigree odds of linkage = 95.9%
45X/ 8/100
46XX 92/100
Unaffected age 46 from pedigree
not showing 17q linkage
45X/ 10/100
46XX 90/100
Unaffected age 66 from pedigree
not showing 17q linkage
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Members of one pedigree exhibited a variety of constitutional
chromosomal variants, several of which were shown to be present in
more than one relative. This complex distribution of cytogenetic
anomalies is illustrated in Figure 13.
One further family illustrated as pedigree A in Figure 2 in which a
germline point mutation in the p53 gene was segregating failed to
fulfil criteria for classification as Li-Fraumeni syndrome (Prosser et
al., 1992). On cytogenetic analysis, two members of this kindred had
both germline p53 mutation and constitutional chromosome
aberrations. These are shown in Figure 14.
In 8 pedigrees an analysis of LOD scores at markers located on
chromosome 17q 12-21 suggested that posterior odds of linkage to a
major breast cancer susceptibility gene on chromosome 17q (BRCA I)
were greater than 75% (Figure 7). In seven of these linked pedigrees,
individuals had been analysed for constitutional chromosome
aberrations. 13 such individuals could be identified as probable
carriers of BRCA I gene mutations on the basis of marker data.
Constitutional chromosome analysis in these were compared with 12
age-matched non-breast cancer gene carriers from these same 7
pedigrees (mean age in each group 36 years, sex ratios approximately
equal). The proportion of cells exhibiting fragile site breaks,
chromosome loss and chromosome anomalies in general were
significantly less in BRCA I carriers than in non-carriers (Table
Xllb). A widespread distribution and frequency of single-cell
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breakpoints throughout the genome in both gene carriers and non-
carriers is illustrated in Figure 15.
130
Figure 13
An Edinburgh pedigree (EDIN 1021 in Figure 1) illustrating
complex karyotypes of individuals.
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An Edinburgh pedigree (Pedigree A in Figure 2) illustrating











































Actual numbers and percentage of cells with chromosomal
anomalies in BRCA1 mutation carriers and non-carriers. Levels of




































Distribution of single cell break-points by chromosome location
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DISCUSSION
1. p53 mutation analysis.
2. Linkage analysis.
i) Two point LOD series.
ii) Penetrance, age-incidence and survival in 17q breast cancer
gene carriers.
3. Structural chromosome analysis.
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1. p53 mutation analysis
Pedigree A in Figure 2 contains 5 close female relatives with breast
cancer and other tumours, yet does not fulfil criteria for classification
as Li-Fraumeni syndrome (Li et al, 1988). Mean age of cancer
development in these 5 individuals is 54 years. This compares with a
mean age of cancer diagnosis of 25 years in 8 Li-Fraumeni syndrome
families with germline p53 gene mutation (Santibanez-Koref et aL,
1991b). It can be inferred from DNA analysis that 4 individuals with
malignancy in pedigree A inherited mutant p53 at codon 267 (no
tissue was available for p53 genotyping from the fifth). This particular
germline mutation had not been previously published, although a
review of 326 tumour and germline p53 gene mutations by De
Fromental and Soussi (1992) lists one small-cell lung cancer cell line
mutation reported within this codon (CGG —> CCG; Arginine —>
Proline).
In pedigree A, the p53 gene mutation is found in 37 and 74 year old
cancer-free relatives. It is therefore possible that the "mutation" is
rather an incidental polymorphism producing a base change without
phenotypic effect. Although codon 267 is situated between highly
conserved regions IV and V of the gene, the arginine residue which it
encodes is evolutionarily conserved throughout species. It is therefore
more likely that the substitution of glutamine for arginine has
produced a non Li-Fraumeni syndrome spectrum of disease with
incomplete lifetime penetrance. Recent reports suggest that screening
of early onset breast cancer patients for germline p53 gene mutation
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can identify carriers within whose family there is a significant
autosomal dominant pattern of breast cancer inheritance but which
lacks the typical features of Li-Fraumeni syndrome (Andersen, 1992).
Pedigree B in Figure 2 fulfils the strict criteria for Li-Fraumeni
syndrome classification (Li et al., 1988). Furthermore, an identical
germline p53 gene mutation in codon 273 (CGT —» CAT; Arginine —»
Histidine) has been reported in a Li-Fraumeni syndrome family from
the USA (De Fromental and Soussi, 1992). In evolutionary terms,
codon 273 in exon 8 of the gene is located within highly conserved
domain V. Codon 273 is the third most frequent site of p53 gene
mutations reported world-wide (7.5% of total mutations in the gene,
(De Fromental and Soussi, 1992).
Pedigree B includes 2 cases of breast cancer, both occurring at
relatively young age. This observation supports that of Santibanez-
Koref et al. (1991a) in which 4 out of 12 individuals with p53 gene
mutations in Li-Fraumeni syndrome families were noted to have early
onset breast cancer and suggests that a small but significant proportion
of early onset familial breast cancer occurs due to inheritance of p53
gene mutations.
2. Linkage analysis
The genetic model for familial breast cancer projected by Iselius et al
(1991) and used in the pedigree analysis program MENDEL (Lange et
141
al., 1988) was chosen in preference to that estimated in the larger
CASH (Cancer and Steroid Hormone) survey (Claus et al1991). One
reason for this was that the population examined by Iselius was
British. It was considered that alternative population studies from the
USA may have been less likely to reflect the genetic pool predominant
in the British Isles. In addition, the association of cases of ovarian
cancer and possibly colonic malignancy and sarcoma found in the
segregation analysis study of Iselius et al. (1991) seemed to be
matched by a similar spectrum of associated malignancy in Edinburgh
breast cancer pedigrees. Furthermore, the estimated gene frequency
and penetrance function agreed with other recent studies in the UK
and other observations in Edinburgh pedigrees which suggested that
the proportion of gene-carrying women who actually develop breast
cancer in their lifetime is rather less than the 92% predicted by the
CASH study.
i) Two-point LOD series
Chromosome 17 short arm
An earlier two point LOD analysis at YNZ 22.1 in pedigree 1
calculated a maximal LOD of +1.8 assuming zero recombination,
providing initial optimism that 17p 13 might be the site of a heritable
breast cancer gene (MacKay, 1989). When additional relatives of
pedigree 1 were screened, however, the maximal LOD was reduced to
+ 1.475. Four further families were screened at this locus (Table III).
Taken together there was no evidence of tight linkage to this region,
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although a maximal LOD of +0.74 was achieved assuming a
recombination fraction of 10%.
YNZ 22.1 is situated at a locus with significant (60%) loss of
constitutional heterozygosity in blood-breast tumour pairs (MacKay et
al., 1988; Coles et al., 1990). It appears from this analysis, however,
that a mutated tumour suppressor gene in this region rarely, if ever,
mediates a heritable trait.
Chromosome 17 long arm;
The results from markers located on chromosome 17q provide strong
evidence for the existence of a heritable breast cancer gene in the
region 17q 12-21. As expected, large families with many affected
individuals such as pedigrees 1, 2 and 11 tend to contribute more to
the overall LOD than small ones (Table X). Average age of onset of
breast cancer was previously found to be important in determining
families likely to be linked to 17q (Hall et al., 1990, 1992). The
present study provides support for this, with a few highly positive
LOD scores occurring in families where there is a young average age
of onset. This observation may be due in part to the nature of the
model estimated by segregation analysis studies and used in the
pedigree analysis. The model considers breast cancer at young age as
less likely to be sporadic, and therefore attributes greater significance
to the associated allele data, making LOD scores more highly positive
if disease and marker are linked. In families 84 and 1021, average age
of onset of breast cancer is 60.7 and 56.0 respectively, and LOD scores
from these families do not contribute towards overall positive linkage.
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Pedigree 84 also fulfils the criteria for hereditary non-polyposis
colorectal carcinoma (HNPCC) as defined by the Collaborative Group
in HNPCC. (Hakala et al., 1991). There is current debate as to whether
this syndrome is associated with a significant increase in breast cancer
risk (Lynch et al., 1991).
The recombination-exclusion map presented in Figure 5 reveals that 5
linked pedigrees contain critical recombinants in affected individuals
involving markers on 17q. Two critical recombinants exclude regions
telomeric to 42D6 and 3 exclude regions centromeric to MFD 188.
42D6 and MFD 188 flank a region 5 to 10 cM in length. Pedigree
structures with markers illustrated in Figures 6a and 6b reveal that,
although the precise point of recombination is difficult to identify
because of the extensive nature of some pedigrees, the evidence
suggests that a breast cancer susceptibility gene might be located
between these markers.
Because all bilateral breast and ovarian cancer alleles typed at 42D6
and MFD 188 also co-segregated with other breast cancer or other
ovarian cancer in the same pedigree, it seemed reasonable to assume
that most cases of ovarian cancer in Edinburgh pedigrees were linked
to a 17q gene. Linkage analysis in those pedigrees with either bilateral
breast cancer or ovarian cancer was therefore employed under new
assumptions that these phenotypes endowed the individual with a
likelihood of carrying the gene equivalent to that for breast cancer at
age 25. This resulted in overall increases in summated LOD scores
(Table X).
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The association between breast cancer and ovarian cancer is well
known (Lynch and Kullander, 1987b) and two recent studies have
reported a high proportion of allele loss using CMM86 in ovarian
tumours (Sato et al., 1991; Foulkes et al., 1991). Bilateral breast
cancer has also been associated with familial disease (Iselius et al.,
1991). According to the retinoblastoma model (Knudson, 1985) the
presence of a breast cancer gene would result in a calculable risk of
one or subsequent tumours in either breast. The actual number of
tumours per gene carrier would be expected to fit closely to a Poisson
distribution. Thus the probability of a second event would be less than
that of a first event, and further reduced by mastectomy. A third event
is rendered impossible after bilateral (complete) mastectomy.
A mechanism to explain why both ovarian and breast cancer might be
precipitated by the same genetic lesion could centre either on the
cyclical nature of epithelial proliferation in these organs, or on their
sensitivity to steroid hormones. The response of breast cancer and
ovarian cancer to hormonal stimuli is complex, but it is at least
possible that the proliferative effect of steroids may promote a second-
copy mutation of a breast or ovarian epithelial cell compromised by an
inherited first-copy defect (Lemon, 1991).
Interestingly, there were no cases of endometrial cancer in the line of
descent of BRCA I carriers in Edinburgh pedigrees. The endometrium,
like the breast and the ovary, responds to steroidal hormones in a
cyclical manner, and endometrial carcinoma has an age-incidence
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curve similar to those for other gynaecological malignancies. Some
epidemiological studies also associate it with familial breast cancer,
although not as part of HNPCC (Lynch et al., 1991).
Cancer of the colon and breast malignancy are also associated in the
syndrome HNPCC. In Edinburgh pedigrees, alleles at 42D6 and
MFD 188 in 9 out of 13 individuals with colon cancer segregated
elsewhere in the pedigree with breast cancer. Since it has been claimed
that as many as 80% of colon cancers may develop as a result of
genetic predisposition (Cannon-Albright et al., 1988) and that 1 in 23
Scottish males and 1 in 33 females develop colon cancer during their
lifetime, then the results from Edinburgh pedigrees carrying BRCA I
mutations suggest this gene might also predispose to colon cancer.
In other types of cancer, the proportion of individuals with alleles co-
segregating with breast cancer was 31 out of 44. There were
insufficient numbers to draw conclusions about linkage of specific
cancer types to BRCA I.
One case of male breast cancer occured in the 15 Edinburgh pedigrees
subjected to linkage analysis. This individual in pedigree 11 appeared
to be a carrier of BRCA I gene mutation (Figure 6b). Although
germline mutations of the androgen receptor gene have been reported
in two brothers with male breast cancer (Wooster et al., 1992), no
previous evidence for linkage of male and female breast cancer to
specific loci exists in the literature.
146
The posterior probability of an individual in a breast cancer family
developing breast cancer is a function of the mode of genetic
transmission, age-specific incidence of sporadic disease, prior
probability of a breast cancer gene in the sibship, age-specific
penetrance of the gene and age of the individual for whom risk is
being assessed. Linkage analysis provides additional data for
determining posterior probability and relies upon an accurate
estimation of recombination distances between flanking markers and
the gene. Computer programs which assess genetic risk and take into
account linked marker data include modifications of LIPED (Ott,
1976) by Winter (1985). Estimates of probability of inheritance of
BRCA I mutation in linked pedigrees can be made without
computerised aids. In individuals from linked Edinburgh pedigrees,
calculations of probability of inheritance of BRCA I mutation ranged
from 0.8% to 98.9%. Lifetime risk of breast cancer ranged from 9.8%
to 87.2%. Although real ethical problems must be considered, these
figures can be useful in a clinical setting through identification of
women most likely to benefit from organ screening or prophylactic
measures.
Individuals belonging to families in which multiple cases of breast
cancer and/or ovarian cancer occur in a line of descent consistent with
autosomal dominant genetic transmission will have a high prior
probability of genetic inheritance of a breast cancer gene. Where there
is also clear evidence for linkage of the disease to 17q markers within
the same pedigree, then unaffected women with marker alleles co-
segregating with the disease will be at much higher risk than is
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currently estimated in analyses devoid of linkage data. Conversely,
unaffected women with flanking marker alleles which do not co-
segregate with the disease elsewhere in the pedigree will be at lower
risk than current estimates. These risks will be more accurately
assessed in large linked pedigrees with multiple cases of breast cancer
and in which LOD scores are greater than +1.5.
Although immediate clinical application of linkage analysis data is
limited, the definitive identification BRCA I is anticipated. Only then
will it be possible to screen individuals for relevant mutations without
reference to laborious family studies in order to define carrier status.
Instead, a single blood sample should suffice to assign a high or low
level of disease risk to breast cancer family members.
ii) Penetrance, age-incidence and survival in 17q breast cancer
gene carriers.
Genetic penetrance of the BRCA I gene recorded here (Figure 10) is
similar to that observed by the International Breast Cancer Linkage
Consortium (Easton et al., 1993). The plateau of the curve appears to
be reached at earlier age than that estimated in segregation analysis
studies (Claus et al., 1991; Iselius et al., 1991). One explanation for
this could be that BRCA I-linked pedigrees are chosen precisely
because they contain multiple cases of breast cancer and so are pre¬
selected for high rates of disease penetrance. Equally there may be
genetic heterogeneity within the totality of heritable breast cancer,
with approximately equal contribution from a highly penetrant BRCA
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I gene and much less penetrant additional genes (such as the p53 and
the ataxia telangiectasia genes) and perhaps other genes which remain
to be identified. Although germline p53 gene mutation is considered
highly penetrant in the sarcomas, carcinomas and leukaemias of
classic Li-Fraumeni syndrome families, recent studies suggest it may
be much less so in heritable breast cancer (Prosser et al., 1992).
Furthermore, if heterozygosity for the ataxia telangiectasia gene does
indeed signify increased risk of breast cancer, then it appears likely
that its penetrance is less than that of BRCA I. (Swift et al., 1990;
Borresen et al., 1990).
The genetic model produced by segregation analysis (in which early
onset of disease is assumed to be relatively more likely in gene carriers
than non-gene carriers and in which modifications of the analysis
allow bilateral disease or diagnosis of ovarian cancer to increase the
likelihood of carrier status) affects overall odds of linkage. It was
therefore expected that the age-incidence curve for BRCA I mutation
carriers would be shifted to the left of that for the general population
(Figure 11) and that bilateral breast cancer should occur in 13 out of
35 (37%) of affected BRCA I mutated individuals. This figure is
similar to the 33% bilaterality rate computed for "totality of breast
cancer" gene carriers in segregation analysis studies (Iselius et al.,
1991).
It is a widely held axiom that early-onset breast cancer is a more
aggressive disease than that which occurs in older women (Nemoto et
al., 1980). At least one study, however, reveals that although heritable
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breast cancer has an age-incidence curve shifted in favour of early-
onset disease, the familial form of malignancy may result in
significantly better survival than that in breast cancer as a whole
(Albano et al., 1982).
The survival curve for the affected BRCA I mutation carriers (Figure
12) may indicate a more optimistic prognosis than that for breast
cancer in the general population. Is it possible that BRCA I mutation
carriers have a spurious survival advantage based on favourable
tumour stage or selection for longevity? There is no evidence from
epidemiological studies that tumour stage at diagnosis in breast cancer
pedigrees differs from that in the general population (Albano et al.,
1982), and in Edinburgh families no selective screening of individuals
had been instituted prior to BRCA I genotyping. In the past, DNA
analysis through blood sampling was only possible in surviving
individuals, thus selection of pedigrees with a bias towards prolonged
breast cancer survival was likely in order to obtain linkage data. The
current procedure for genotyping at loci 42D6 and MFD 188 however
involves DNA typing from additional deceased individuals since fixed
paraffin-wax embedded tissue can be utilised which eliminates the
bias towards breast cancer survival. This absence of bias is confirmed
by the lack of any correlation between breast cancer survival in linked
pedigrees and maximal odds of linkage for each family (Table XIII).
It is therefore possible that the survival data reflects a real phenotypic
effect of BRCA I mutation. If these findings are confirmed in other
larger series, than future analysis of survival data from BRCA I
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mutation carriers in breast screening programmes must take into
account this pre-existing survival advantage to avoid an over-




Maximal odds of linkage, mean survival of deceased and surviving




Pedigree Maximal Rank Mean Survival Rank Mean Survival Rank
Identification Odds of of Deceased of Surviving
number Linkage Breast Cancer Breast Cancer
(%) Cases /Years Cases/Years
2 99.9 1 1.5 8 18.3 2
11 99.2 2 5.5 6 4.0 7
30 95.9 3 11.0 4 2.5 8
2000 94.6 4 All Alive 1 = 7.5 5
37 92.3 5 3.5 7 29.5 1
1 88.8 6 6.0 5 17.0 3
16 85.5 7 13.0 3 5.0 6
3 79.2 8 All Alive 1 = 10.7 4
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3. Structural chromosome analysis.
The complex chromosomal variants found in the pedigree illustrated in
Figure 13 suggest that there may be some heritable predisposition to
cytogenetic aberrations in this family. A putative causative gene might
be inherited in autosomal dominant fashion with consequent
accumulation of non-lethal chromosomal variants in both gene carriers
and non-gene carriers alike. In this situation, de-novo chromosome
rearrangements will occur only in gene carriers at meiosis. Non-gene
carriers will inherit previously accumulated anomalies and pass on
these to their progeny. Perhaps a gene predisposing to cytogenetic
aberrations also produces a generalised genetic instability in which
breast and other cancers become more likely. In these respects it
appears to share striking characteristics with the ataxia telangiectasia
gene (Gatti et al., 1988).
Chromosome analysis in the non Li-Fraumeni syndrome cancer family
illustrated in Figure 14 reveals two individuals with chromosome
abnormalities. No individuals exhibited detectable abnormal
phenotypes. One individual has Turner's syndrome (XO), the other an
inversion involving chromosome 5. Both individuals inherited a
germline p53 gene mutation. It is recognised that cytogenetic analyses
of peripheral blood leukocytes in Li-Fraumeni syndrome family
members reveal chromosome loss in a greater than expected
proportion of cells (Bischoff et al., 1990) and it is therefore possible
that the constitutional chromosomal anomalies found in two carriers of
the mutant p53 gene reflect a general chromosome instability
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produced by mutant p53 protein; an instability which is apparently not
exhibited in carriers of a 17q breast cancer susceptibility cancer gene.
Table Xllb reveals that there is a significant reduction in single cell
chromosome anomalies in general (and in chromosome loss and
fragile sites expression specifically) in age-matched BRCA I mutation
carriers unaffected by breast cancer compared with their non-gene
carrying relatives. Figure 15 shows that no genomic regions are
preferentially targeted for abnormalities which occur in BRCA I
carriers. This analysis provides no support for a hypothesis involving
increased DNA instability as a mechanism of action for BRCA I; in
fact the opposite appears more likely. Interestingly, a comparable
observation was reported by Mitchell et al., (1991). They found that
lymphocytes in women unaffected by breast cancer but with a strong
family history of the disease exhibited no increases in susceptibility to
fragile site expression and induction by aphidicolin compared with
controls. Perhaps carriers of breast cancer susceptibility gene
mutation, heterozygous at the BRCA I locus, compensate in some way
for the reduced level of crucial BRCA I gene product though increased
expression of other genes important in cell cycle control and which
act secondarily to stabilise cell division, thereby increasing rates of
DNA repair prior to mitosis.
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Conclusion
These genetic studies on peripheral blood lymphocytes of individuals
from breast cancer pedigrees have assisted in the localisation of a
major breast cancer susceptibility gene (BRCA I) on chromosome 17q
12-21 through linkage analysis. They have enabled high-risk women
from both BRCA I and p53 gene mutation carrying families to be
identified and discriminated from their low-risk, non-gene carrying
relatives. Structural chromosome analysis has suggested a role for
DNA instability as a mediator of cancer risk in p53 but not BRCA I
mutation pedigrees. Preliminary survival data may indicate an
improved prognosis in BRCA I mutation carriers with breast cancer
compared with survival in breast cancer in general.
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